var title_f6_49_6928="Insulin plus oral hypoglycemics";
var content_f6_49_6928=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F80026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F80026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Combination insulin and oral hypoglycemic therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 601px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this study, 96 patients who were inadequately controlled with a sulfonylurea drug alone were randomly assigned to receive bedtime intermediate-acting insulin (BI) plus either glyburide, metformin, glyburide plus metformin, or a second injection of intermediate-acting insulin in the morning. After 12 months, the group receiving bedtime insulin plus metformin alone had significantly less weight gain (upper panel) and lower HbA1c values (lower panel) than the other three treatment groups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Yki-Jarvinen, H, Ryysy, L, Nikkila, K, et al, Ann Intern Med 1999; 130:389.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_49_6928=[""].join("\n");
var outline_f6_49_6928=null;
var title_f6_49_6929="Laparosc transuterine entry";
var content_f6_49_6929=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Transuterine entry and insufflation for laparoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transuterine Veress needle insertion. The tenaculum is placed on the anterior lip of the cervix and held under tension to straighten uterine axis. The uterus is anteverted with the Veress needle so that the needle tip is directed away from the sacrum, great vessels, and rectosigmoid colon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     LifeART image copyright &copy;2009 Lippincott Williams &amp; Wilkins. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_49_6929=[""].join("\n");
var outline_f6_49_6929=null;
var title_f6_49_6930="Alternative port placement for appendectomy";
var content_f6_49_6930=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Alternative port placement for appendectomy*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 587px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An open technique is used to enter the peritoneal cavity and place a 5 to 12 mm Hasson trocar at the umbilicus. The laparoscope is introduced through this port and two additional 5 mm ports are placed. As an alternative, the two 5 mm ports can be placed in the \"bikini line\". The surgeon retracts the appendix using a grasper through a right lower quadrant port and dissects using the periumbilical port site (portrayed in red) while the assistant operates the laparoscope through a left lower quadrant port (portrayed in blue). The appendix is removed in a bag through the umbilical port.",
"    <div class=\"footnotes\">",
"     * Port placement and technique may vary amongst laparoscopic surgeons.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_49_6930=[""].join("\n");
var outline_f6_49_6930=null;
var title_f6_49_6931="Patient information: Pacemakers (The Basics)";
var content_f6_49_6931=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15666\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/61/27602\">",
"         Medtronic Adapta&reg; Pacemaker",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?8/16/8451\">",
"         Patient information: Atrial flutter (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/46/8931\">",
"         Patient information: Bradycardia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/34/37410\">",
"         Patient information: Cardiac resynchronization therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/60/38850\">",
"         Patient information: Implantable cardioverter-defibrillators (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/40/19075\">",
"         Patient information: Sick sinus syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/5/36946\">",
"         Patient information: Syncope (fainting) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/56/23427\">",
"         Patient information: Wolff-Parkinson-White syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/16/261\">",
"         Patient information: Atrial fibrillation (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/20/11589\">",
"         Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/16/20741\">",
"         Patient information: Pacemakers (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/9/4245\">",
"         Patient information: Syncope (fainting) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pacemakers (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/pacemakers-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9034798\">",
"      <span class=\"h1\">",
"       What is a pacemaker?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A pacemaker is a device that sits under the skin near a person&rsquo;s heart. A pacemaker can treat an abnormal heart rate. &ldquo;Heart rate&rdquo; is the term doctors use to describe how fast a person&rsquo;s heart is beating.",
"     </p>",
"     <p>",
"      Normally, each person has a built-in electrical system in the heart that controls his or her heart rate. A person&rsquo;s heart needs to beat at a normal rate in order to pump blood to all parts of the body. Sometimes, a person&rsquo;s built-in electrical system does not work the right way. This can cause a person&rsquo;s heart to beat too slowly or too fast.",
"     </p>",
"     <p>",
"      Different conditions, such as certain heart problems, can cause a person&rsquo;s heart rate to be abnormal.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9034813\">",
"      <span class=\"h1\">",
"       How does a pacemaker work?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A pacemaker sends electrical signals to the heart. These signals cause the heart to beat at a normal rate. Most of the time, pacemakers are used to treat a heart rate that is too slow. But pacemakers can also prevent or control a heart rate that is too fast.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9034828\">",
"      <span class=\"h1\">",
"       Who might need a pacemaker?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A person might need a pacemaker if he or she has an abnormal heart rate and has symptoms. These symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fainting",
"       </li>",
"       <li>",
"        Feeling dizzy or light-headed",
"       </li>",
"       <li>",
"        Feeling your heart pounding",
"       </li>",
"       <li>",
"        Feeling confused or more tired than usual",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9034843\">",
"      <span class=\"h1\">",
"       What does a pacemaker look like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A pacemaker has 2 parts:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A &ldquo;pulse generator&rdquo; (",
"        <a class=\"graphic graphic_picture graphicRef67059 \" href=\"UTD.htm?26/61/27602\">",
"         picture 1",
"        </a>",
"        ) &ndash; This is a thin metal case with a battery and small computer in it. The pulse generator creates and sends electrical signals. A doctor can pre-set the computer to tell the pulse generator when to send electrical signals.",
"       </li>",
"       <li>",
"        Wires, also called &ldquo;leads&rdquo; &ndash; The wires connect the pulse generator to the heart. Electrical signals can travel from the pulse generator through the wires to the heart. Information about how the heart is working can also travel from the heart back to the pulse generator.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9034858\">",
"      <span class=\"h1\">",
"       Do all pacemakers work the same way?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Pacemakers can work in different ways. A pacemaker can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Send electrical signals all of the time or some of the time &ndash; Some pacemakers send electrical signals at a steady rate all of the time. Others send electrical signals only when a person&rsquo;s heart rate is too slow or too fast.",
"       </li>",
"       <li>",
"        Send electrical signals to one or more parts of the heart",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9034873\">",
"      <span class=\"h1\">",
"       What is a &ldquo;temporary pacemaker&rdquo;?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A temporary pacemaker is a pacemaker that is used for a short time, usually when a person is in the hospital. The pulse generator of a temporary pacemaker is not put inside the body. People might have a temporary pacemaker if they have a condition that will get better soon. They might also have a temporary pacemaker as a short-term treatment until they get a pacemaker put in their body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9034888\">",
"      <span class=\"h1\">",
"       What happens after I get a pacemaker?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After you get a pacemaker, you will need to follow up with your doctor on a regular basis. He or she might do a test called an &ldquo;electrocardiogram&rdquo; (ECG). An ECG measures the electrical activity in the heart. Your doctor will also check to make sure that your pacemaker is working the right way.",
"     </p>",
"     <p>",
"      Some people might need to have the pulse generator part of their pacemaker replaced in the future. This is because the battery in the pulse generator usually lasts 5 to 8 years. Wires do not usually need to be replaced.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9034903\">",
"      <span class=\"h1\">",
"       What else should I do if I have a pacemaker?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have a pacemaker, you will need to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Avoid certain electric or magnetic sources or equipment &ndash; Your doctor will tell you which electric or magnetic sources or equipment you can be near, and which ones you should avoid. For example, people with a pacemaker can be near televisions and radios. But some people with a pacemaker should not walk through a metal detector at the airport. (People who cannot walk through a metal detector can have a security search by hand instead.)",
"       </li>",
"       <li>",
"        Let all of your doctors and nurses know that you have a pacemaker &ndash; Some procedures and tests are safe for people with a pacemaker, but others are not. For example, people with a pacemaker should not have a type of imaging test called an MRI scan. Many people with a pacemaker carry an emergency medical card that tells people they have a pacemaker.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9034918\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=see_link\">",
"       Patient information: Implantable cardioverter-defibrillators (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/16/8451?source=see_link\">",
"       Patient information: Atrial flutter (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/56/23427?source=see_link\">",
"       Patient information: Wolff-Parkinson-White syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/40/19075?source=see_link\">",
"       Patient information: Sick sinus syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/5/36946?source=see_link\">",
"       Patient information: Syncope (fainting) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/34/37410?source=see_link\">",
"       Patient information: Cardiac resynchronization therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/46/8931?source=see_link\">",
"       Patient information: Bradycardia (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"       Patient information: Pacemakers (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"       Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"       Patient information: Atrial fibrillation (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/9/4245?source=see_link\">",
"       Patient information: Syncope (fainting) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?6/49/6931?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15666 Version 6.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_49_6931=[""].join("\n");
var outline_f6_49_6931=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9034798\">",
"      What is a pacemaker?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9034813\">",
"      How does a pacemaker work?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9034828\">",
"      Who might need a pacemaker?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9034843\">",
"      What does a pacemaker look like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9034858\">",
"      Do all pacemakers work the same way?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9034873\">",
"      What is a &ldquo;temporary pacemaker&rdquo;?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9034888\">",
"      What happens after I get a pacemaker?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9034903\">",
"      What else should I do if I have a pacemaker?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9034918\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15666\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/61/27602\">",
"      Medtronic Adapta&reg; Pacemaker",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/16/8451?source=related_link\">",
"      Patient information: Atrial flutter (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/46/8931?source=related_link\">",
"      Patient information: Bradycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/34/37410?source=related_link\">",
"      Patient information: Cardiac resynchronization therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=related_link\">",
"      Patient information: Pacemakers (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/40/19075?source=related_link\">",
"      Patient information: Sick sinus syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/9/4245?source=related_link\">",
"      Patient information: Syncope (fainting) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/5/36946?source=related_link\">",
"      Patient information: Syncope (fainting) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/56/23427?source=related_link\">",
"      Patient information: Wolff-Parkinson-White syndrome (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_49_6932="Levocabastine (nasal): Drug information";
var content_f6_49_6932=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levocabastine (nasal): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/55/43891?source=see_link\">",
"    see \"Levocabastine (nasal): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11231185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Livostin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F11231189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"     <li>",
"      Piperidine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11231227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Allergic rhinitis:",
"     </b>",
"     Intranasal: Adults &le;65 years: Two sprays in each nostril twice daily; if necessary, may increase dose to 2 sprays 3-4 times daily; consider therapy discontinuation if no response within 3 days. Continuous treatment &gt;10 weeks has not been evaluated.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F11231226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Allergic rhinitis:",
"     </b>",
"     Intranasal: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11231228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F11231248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Microsuspension, intranasal, as hydrochloride [spray]:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Livostin&reg;: 0.05% [50 mcg/spray] (15 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11231195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11231246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intranasal: Shake bottle well before each use. Prior to initial use, bottle should be primed until a fine spray is delivered. Instruct patients to blow nose and clear nasal passages before administering spray and to inhale nasally while spraying.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11231190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic treatment of allergic rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11231184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Levocabastine may be confused with levobunolol, levOCARNitine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Livostin&reg; may be confused with lovastatin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Livostin [Canada and multiple international markets] may be confused with Limoxin brand name for ambroxol [Indonesia] and amoxicillin [Mexico]; Lovastin brand name for lovastatin [Malaysia, Poland, Singapore]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11231198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Most adverse reactions are transient; incidence often similar to placebo.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Somnolence (4%), headache (3%), fatigue (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Xerostomia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasal irritation (5%), epistaxis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Aggravated nasal obstruction, allergic reactions, application site reactions (nasal discomfort, nasal edema), bronchospasm, dizziness, dry nose, dyspnea, eyelid edema, external ear pruritus, facial edema, hearing decreased, hypersensitivity, malaise, nasal pruritus, rhinorrhea, tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11231193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to levocabastine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11231194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS effects: Not generally associated with significant sedation; patients experiencing drowsiness should be cautioned about performing dangerous tasks such as driving or operating machinery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use caution; limited data available regarding use in this population.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11304611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11231191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies when using oral doses much larger than the equivalent maximum human nasal dose.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11231192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following intranasal application, minute amounts of levocabastine have been detected in human breast milk (Simons 1999).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13733203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Livocab (DE, NL);",
"     </li>",
"     <li>",
"      Livostin (AT, AU, BE, CH, CL, CZ, DK, FI, GR, IL, JP, NO, NZ, PT, SE, VE, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11231244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent, selective histamine H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor antagonist",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11231204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Incomplete, within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic (minimal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 60% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, elimination: 33 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (65% to 70% as unchanged drug); feces (10% to 20% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hampel FC Jr, Martin BG, Dolen J, et al, &ldquo;Efficacy and Safety of Levocabastine Nasal Spray for Seasonal Allergic Rhinitis,&rdquo;",
"      <i>",
"       Am J Rhino",
"      </i>",
"      , 1999, 13(1):55-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/49/6932/abstract-text/10088031/pubmed\" id=\"10088031\" target=\"_blank\">",
"        10088031",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simons FER and Simons KJ, &ldquo;Clinical Pharmacology of New Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Receptor Antagonists,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1999, 36(5):329-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/49/6932/abstract-text/10384858/pubmed\" id=\"10384858\" target=\"_blank\">",
"        10384858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16009 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7727F3B860-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_49_6932=[""].join("\n");
var outline_f6_49_6932=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231185\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231189\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231227\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231226\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231228\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160298\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231248\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231195\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231246\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231190\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231184\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231198\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231193\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231194\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299588\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11304611\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231191\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231192\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13733203\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231244\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231204\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16009\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16009|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/55/43891?source=related_link\">",
"      Levocabastine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22179?source=related_link\">",
"      Levocabastine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/62/41955?source=related_link\">",
"      Levocabastine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_49_6933="Nephropathy induced by aristolochic acid (AA) containing herbs";
var content_f6_49_6933=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nephropathy induced by aristolochic acid (AA) containing herbs",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/49/6933/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6933/contributors\">",
"     Marc E De Broe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/49/6933/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6933/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/49/6933/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6933/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/49/6933/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1991, physicians in Belgium noted an increasing number of women who presented with acute, often near end-stage renal disease following exposure to aristolochic acid (AA) at a weight reduction clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. An initial survey of seven nephrology centers in Brussels identified 14 women under the age of 50 who had presented with advanced renal failure due to biopsy proven chronic tubulointerstitial nephritis over a three year period; nine of these patients had been exposed to the same slimming regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/1\">",
"     1",
"    </a>",
"    ]. A total of more than 300 cases have been identified, a third of whom have already undergone renal transplantation.",
"   </p>",
"   <p>",
"    The epidemiology is unknown, as is the risk for development of severe renal damage. However, the publication of case reports from several countries in Europe and Asia, particularly in China, indicate that the incidence of herbal medicine-induced nephrotoxicity is more common than previously thought [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major lesion, which is located principally in the cortex, is extensive interstitial fibrosis with atrophy and loss of the tubules. Cellular infiltration of the interstitium is scarce. Thickening of the walls of the interlobular and afferent arterioles result from endothelial cell swelling. The glomeruli are relatively spared and immune deposits are not observed. These findings suggest that the primary lesions may be centered in the vessel walls, thereby leading to ischemia and interstitial fibrosis.",
"   </p>",
"   <p>",
"    An extremely high incidence of cellular atypia and urothelial (transitional cell) carcinoma of the renal pelvis, ureter, and bladder has been associated with AA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aristolochic acid (AA) in combination with the vasoconstrictive appetite suppressants, fenfluramine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/23/8565?source=see_link\">",
"     diethylpropion",
"    </a>",
"    , diuretics, and other potential nephrotoxins&nbsp;may underlie AA nephropathy. Support for AA as a potential nephrotoxin is provided by findings in animal models (rabbit, rat and mice) of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. In one study, for example, rabbits were given intraperitoneal injections of AA (0.1 mg",
"    <span class=\"nowrap\">",
"     AA/kg",
"    </span>",
"    5 days a week for 17 to 21 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/10\">",
"     10",
"    </a>",
"    ]. Histologic examination of the kidneys and genitourinary tract revealed renal hypocellular interstitial fibrosis, and atypical and malignant uroepithelial cells.",
"   </p>",
"   <p>",
"    However, it is not clear if AA has been part of the herbal preparations used by all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/1\">",
"     1",
"    </a>",
"    ]. Furthermore, AA (0.15",
"    <span class=\"nowrap\">",
"     mg/tablet)",
"    </span>",
"    has been used as an immunomodulatory drug for 20 years in Germany by thousands of patients, sometimes in doses comparable to that found in AA-containing slimming regimens; despite this exposure, there is no report relating chronic tubulointerstitial nephritis to AA in Germany.",
"   </p>",
"   <p>",
"    In addition to AA, patients with AA nephropathy also received the appetite suppressants, fenfluramine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/23/8565?source=see_link\">",
"     diethylpropion",
"    </a>",
"    ; these agents have vasoconstrictive properties [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Together, these observations suggest that the fast-developing chronic tubulointerstitial renal disease may have been caused by combined exposure to both a potent nephrotoxic substance, AA, and to renal vasoconstrictors,",
"    <span class=\"nowrap\">",
"     fenfluramine/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/23/8565?source=see_link\">",
"      diethylpropion",
"     </a>",
"     .",
"    </span>",
"    However, studies in animals found that the combination of AA and high doses of fenfluramine resulted in a comparable degree of interstitial fibrosis as AA alone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The necessity to stimulate the intrarenal renin-angiotensin system (salt deprivation) to obtain fibrointerstitial lesions are consistent with the combined exposure concept observed with several potential nephrotoxins [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/15\">",
"     15",
"    </a>",
"    ]. Blockade of the renin-angiotensin system, however, does not prevent renal interstitial fibrosis by AA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/17\">",
"     17",
"    </a>",
"    ]. How far transdifferentiation and apoptosis play an important role in this fast developing type of chronic tubulointerstitial disease of the kidneys is still not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/18\">",
"     18",
"    </a>",
"    ]. One study suggests that AA induces tubular epithelial cell death via apoptosis by dephosphorylation of STAT3 and posttranslational activation of p53, supporting the hypothesis that p53 promotes renal injury in AA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another uncertain factor is why only some patients exposed to the same herbal preparations develop renal disease. Women appear to be at greater risk than men. Other possibly important factors include toxin dose, batch-to-batch variability in toxin content, individual differences in toxin metabolism, and a genetically determined predisposition toward nephrotoxicity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    carcinogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of the two studies showing a link between AA and carcinogenesis, an increased dose of AA was associated with an enhanced risk of carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/8\">",
"     8",
"    </a>",
"    ]. Tissue samples revealed AA-related DNA adducts, indicating a possible mechanism underlying the development of malignancy. The presence of these adducts was noted in another report of two patients with urothelial malignancy and AA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another possible factor is the abnormal function of p53, a known tumor suppressor gene. In the second study showing a link between the nephropathy and carcinogenesis, all atypical cells were found to overexpress this protein, thereby suggesting the presence of a mutation in the gene [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19878?source=see_link\">",
"     \"Balkan endemic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It was found that, in vitro (opossum kidney cell line) and in vivo (rat), proximal tubular injury occurs early after AA intoxications. There is a link between specific AA &ndash; DNA adduct formation and decreased megalin expression and inhibition of",
"    <span class=\"nowrap\">",
"     receptor/mediated",
"    </span>",
"    endocytosis of low molecular weight proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/22\">",
"     22",
"    </a>",
"    ]. Cytotoxicity data suggest that the nitro and methoxy groups are critical determinants of the nephrotoxic potency of AA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRESENTATION AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected patients typically present with renal insufficiency with other findings that are typical of a primary tubulointerstitial disease. The blood pressure is either normal or only mildly elevated, protein excretion is only moderately increased (less than 1.5",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    and the urine sediment reveals only a few red and white cells. The elevation in protein excretion consists of both albumin and low molecular weight proteins that are normally filtered and reabsorbed by proximal tubular cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/24\">",
"     24",
"    </a>",
"    ]. Thus, tubular dysfunction contributes to the proteinuria.",
"   </p>",
"   <p>",
"    The plasma creatinine concentration at presentation has ranged from 1.4 to 12.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (123 to 1122",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/2\">",
"     2",
"    </a>",
"    ]. Follow-up studies have revealed relatively stable renal function in most patients with an initial plasma creatinine concentration below 2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (176",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/25\">",
"     25",
"    </a>",
"    ]. However, progressive renal failure resulting in eventual dialysis or transplantation may ensue in patients with more severe disease even if further exposure to AA is prevented. The risk for progressive disease increases with the duration of exposure.",
"   </p>",
"   <p>",
"    An extremely similar clinical and pathologic process has been reported in a group of patients from Taiwan who had ingested a selection of uncontrolled traditional AA that differed from those of the slimming regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/3\">",
"     3",
"    </a>",
"    ]. Despite discontinuation of these remedies, progressive renal failure was common. Although the exact correlation between this disorder and traditional AA nephropathy associated with the slimming regimen is unclear, toxins common to different herbal remedies may cause interstitial renal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no proven effective therapy for this disorder, which typically presents with marked interstitial fibrosis but not prominent inflammation. An uncontrolled study suggested that corticosteroids may slow the rate of loss of renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The high incidence of cellular atypia of the genitourinary tract suggests that, at a minimum, these patients should undergo regular surveillance for abnormal urinary cytology. Whether more aggressive management strategies, such as bilateral native nephroureterectomies (particularly in those undergoing renal transplantation), are required is unclear. Findings from one report support the more aggressive option [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal transplantation is an effective modality for those who progress to end-stage renal disease. One report noted no recurrence in five such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6933/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aristolochic acid (AA) nephropathy is an interstitial nephritis related to AA that was first described in 1991. A high incidence of cellular atypia and urothelial (transitional cell) carcinoma of the renal pelvis, ureter, and bladder has been associated with this disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major histologic lesion in the kidney is interstitial fibrosis with atrophy and loss of the tubules in the renal cortex. Thickening of the walls of the interlobular and afferent arterioles may be observed. Cellular infiltration of the interstitium is scarce and glomeruli are spared. Immune deposits are not present. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aristolochic acid (AA) in combination with the vasoconstrictive appetite suppressants, fenfluramine and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/23/8565?source=see_link\">",
"       diethylpropion",
"      </a>",
"      , diuretics, and other potential nephrotoxins&nbsp;may underlie AA nephropathy. Stimulation of the intrarenal renin-angiotensin system likely contributes to the lesion. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for development of AA nephropathy include female gender, toxin dose, and a genetically determined predisposition toward nephrotoxicity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      carcinogenesis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Affected patients typically present with renal insufficiency and normal or only mildly elevated blood pressure. Protein excretion is only moderately increased (less than 1.5",
"      <span class=\"nowrap\">",
"       g/day),",
"      </span>",
"      and the urine sediment reveals only a few red and white cells. The elevation in protein excretion consists of both albumin and low molecular weight proteins. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Presentation and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific therapy for AA nephropathy although one uncontrolled study suggests that corticosteroids may slow the rate of loss of renal function. Renal transplantation is an effective modality for those who progress to end-stage renal disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the high incidence of cellular atypia of the genitourinary tract, patients should undergo regular surveillance for abnormal urinary cytology. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/1\">",
"      Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993; 341:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/2\">",
"      Depierreux M, Van Damme B, Vanden Houte K, Vanherweghem JL. Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am J Kidney Dis 1994; 24:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/3\">",
"      Yang CS, Lin CH, Chang SH, Hsu HC. Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. Am J Kidney Dis 2000; 35:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/4\">",
"      Wu Y, Liu Z, Hu W, Li L. Mast cell infiltration associated with tubulointerstitial fibrosis in chronic Aristolochic Acid Nephropathy. Hum Exp Toxicol 2005; 24:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/5\">",
"      Guy, JY, Chen, HC, Tsai, JF, Chuang, LY. Herbal therapy is associated with the risk of CKD in adults not using analgesics in Taiwan. Am J Kidney Dis 2007; 49:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/6\">",
"      Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 2008; 74:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/7\">",
"      Cosyns JP, Jadoul M, Squifflet JP, et al. Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis 1999; 33:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/8\">",
"      Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000; 342:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/9\">",
"      Isnard Bagnis C, Deray G, Baumelou A, et al. Herbs and the kidney. Am J Kidney Dis 2004; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/10\">",
"      Cosyns JP, Dehoux JP, Guiot Y, et al. Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? Kidney Int 2001; 59:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/11\">",
"      Debelle FD, Nortier JL, De Prez EG, et al. Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J Am Soc Nephrol 2002; 13:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/12\">",
"      Van Vleet TR, Schnellmann RG. Toxic nephropathy: environmental chemicals. Semin Nephrol 2003; 23:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/13\">",
"      Nortier JL, Vanherweghem JL. For patients taking herbal therapy--lessons from aristolochic acid nephropathy. Nephrol Dial Transplant 2007; 22:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/14\">",
"      Zhou L, Fu P, Huang XR, et al. Mechanism of chronic aristolochic acid nephropathy: role of Smad3. Am J Physiol Renal Physiol 2010; 298:F1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/15\">",
"      De Broe ME. On a nephrotoxic and carcinogenic slimming regimen. Am J Kidney Dis 1999; 33:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/16\">",
"      Debelle F, Nortier J, Arlt VM, et al. Effects of dexfenfluramine on aristolochic acid nephrotoxicity in a rat model for Chinese-herb nephropathy. Arch Toxicol 2003; 77:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/17\">",
"      Debelle FD, Nortier JL, Husson CP, et al. The renin-angiotensin system blockade does not prevent renal interstitial fibrosis induced by aristolochic acids. Kidney Int 2004; 66:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/18\">",
"      Pozdzik AA, Salmon IJ, Debelle FD, et al. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney Int 2008; 73:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/19\">",
"      Zhou L, Fu P, Huang XR, et al. Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. J Am Soc Nephrol 2010; 21:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/20\">",
"      Diamond JR, Pallone TL. Acute interstitial nephritis following use of tung shueh pills. Am J Kidney Dis 1994; 24:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/21\">",
"      Lord GM, Cook T, Arlt VM, et al. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 2001; 358:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/22\">",
"      Lebeau C, Arlt VM, Schmeiser HH, et al. Aristolochic acid impedes endocytosis and induces DNA adducts in proximal tubule cells. Kidney Int 2001; 60:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/23\">",
"      Balachandran P, Wei F, Lin RC, et al. Structure activity relationships of aristolochic acid analogues: toxicity in cultured renal epithelial cells. Kidney Int 2005; 67:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/24\">",
"      Kabanda A, Jadoul M, Lauwerys R, et al. Low molecular weight proteinuria in Chinese herbs nephropathy. Kidney Int 1995; 48:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/25\">",
"      Reginster F, Jadoul M, van Ypersele de Strihou C. Chinese herbs nephropathy presentation, natural history and fate after transplantation. Nephrol Dial Transplant 1997; 12:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/26\">",
"      Vanherweghem JL. Nephropathy and herbal medicine. Am J Kidney Dis 2000; 35:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6933/abstract/27\">",
"      Vanherweghem JL, Abramowicz D, Tielemans C, Depierreux M. Effects of steroids on the progression of renal failure in chronic interstitial renal fibrosis: a pilot study in Chinese herbs nephropathy. Am J Kidney Dis 1996; 27:209.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7206 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.97.94.19-F6CCE2A0D3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_49_6933=[""].join("\n");
var outline_f6_49_6933=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRESENTATION AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19878?source=related_link\">",
"      Balkan endemic nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_49_6934="Granulomatous lung involvement in CGD";
var content_f6_49_6934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F55108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F55108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Granulomatous lung involvement in CGD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High resolution computed tomography (HRCT) scan in a patient with chronic granulomatous disease, nonproductive cough, and pleuritic chest pain. Nodular area of consolidation in right middle lobe was persistent for several months despite antibiotic therapy. Lung biopsy revealed granulomatous inflammation. Bilateral areas of decreased vascularity and attenuation are also noted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Godoy MCB, Vos PM, Cooperberg PL, et al. Chest radiographic and CT manifestations of chronic granulomatous disease in adults. AJR Am J Roentgenol 2008; 191:1570. Reprinted with permission from: the American Journal of Roentgenology. Copyright &copy; 2008 American Roentgen Ray Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_49_6934=[""].join("\n");
var outline_f6_49_6934=null;
var title_f6_49_6935="Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis";
var content_f6_49_6935=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/49/6935/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6935/contributors\">",
"     John Varga, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6935/contributors\">",
"     Virginia Steen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/49/6935/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6935/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6935/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/49/6935/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6935/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/49/6935/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary complications of systemic sclerosis (SSc) are both frequent and the leading cause of SSc-related death [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The most common pulmonary manifestations of SSc are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulmonary arterial hypertension (PAH)",
"     </li>",
"     <li>",
"      Interstitial lung disease (ILD)",
"     </li>",
"     <li>",
"      Pulmonary hypertension (PH) due to ILD",
"     </li>",
"     <li>",
"      A combination of ILD and PAH",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The classification, definition, risk factors, screening, and prognosis of SSc-associated PAH are reviewed here, while the clinical manifestations, diagnosis, and treatment of SSc-associated PAH are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26329?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations of systemic sclerosis (scleroderma) lung disease\", section on 'Pulmonary arterial hypertension'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26342?source=see_link\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other types of SSc-related lung disease are also discussed separately, including ILD and ILD-associated PH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26329?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations of systemic sclerosis (scleroderma) lung disease\", section on 'Interstitial lung disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/19/7482?source=see_link\">",
"     \"Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16889?source=see_link\">",
"     \"Pulmonary hypertension associated with interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) classifies patients with pulmonary hypertension into five groups, as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef66348 \" href=\"UTD.htm?42/38/43628\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients in the first group are considered to have pulmonary arterial hypertension (PAH). In contrast, patients in the remaining four groups are considered to have pulmonary hypertension (PH):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group 2 PH consists of patients who have pulmonary venous hypertension, which is usually due to left heart disease",
"     </li>",
"     <li>",
"      Group 3 PH includes patients who have PH due to lung disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chronic hypoxemia (ie, interstitial lung disease, chronic obstructive airways disease, and obstructive sleep apnea)",
"     </li>",
"     <li>",
"      Group 4 PH consists of patients with chronic thromboembolic pulmonary hypertension",
"     </li>",
"     <li>",
"      Group 5 PH includes patients whose PH is of uncertain cause and likely multifactorial",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When all five groups are described collectively, the term PH is used.",
"   </p>",
"   <p>",
"    Systemic sclerosis (SSc) is unique among the different forms of PH because it can be associated with group 1 PAH or group 3 PH. In addition, patients with SSc frequently have diastolic dysfunction and group 2 PH. As a result, the precise classification of the type of PH can be challenging in patients with SSc.",
"   </p>",
"   <p>",
"    Group 1 PAH is the focus of this review. Group 2 PH and group 3 PH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16889?source=see_link\">",
"     \"Pulmonary hypertension associated with interstitial lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Group 2 PH'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Group 3 PH'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH) is defined as a mean pulmonary artery pressure greater than 25 mmHg at rest (measured by right heart catheterization) with a wedge pressure less than or equal to 15 mmHg in a patient who has systemic sclerosis without significant coexisting interstitial lung disease and chronic hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to recognize patients who are at increased risk for developing systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH). Vigilant monitoring and early detection facilitates the timely initiation of therapy, which improves symptoms and may prolong survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26342?source=see_link&amp;anchor=H3#H3\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment\", section on 'Directed therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following risk factors for PAH have been identified in patients with SSc:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long-standing limited cutaneous SSc with a positive anti-centromere antibody. The total burden of cutaneous telangiectasias correlates positively with the risk of PAH [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with diffuse cutaneous SSc tend to develop PAH less commonly; however, those with a nucleolar pattern of anti-nuclear antibody (ANA) are at increased risk [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Progressive decrease of the diffusion capacity (DLCO) over serial measurements. This was demonstrated by a case control study of 212 patients with limited cutaneous SSc [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/7\">",
"       7",
"      </a>",
"      ]. Patients with PAH were matched to patients without PAH according to age, gender, extent of skin involvement, and disease duration. The mean DLCO was 52 percent of predicted five years before PAH developed. A linear decline of 50 percent was found over a 10 to 15 year period among patients who developed PAH. In contrast, the DLCO remained unchanged in patients who did not develop PAH.",
"     </li>",
"     <li>",
"      Exercise-induced PH on right heart catheterization [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Nearly 20 percent of patients with SSc and exercise-induced PH may progress to PAH, according to an observational study [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to these risk factors, patients with Scl 70 autoantibodies are more likely to have PH associated with interstitial lung disease (group 3 PH). Patients with SSc who have anti-RNA polymerase III autoantibodies characteristically have extensive skin involvement and increased risk for scleroderma renal crisis, but uncommonly develop PAH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with systemic sclerosis (SSc) who have never been diagnosed with pulmonary vascular disease have been screened for pulmonary arterial hypertension (PAH) in numerous observational studies. Doppler echocardiography was the most common screening method, but exercise echocardiography and diagnostic algorithms were also used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Doppler echocardiography &ndash; In a study that included 669 patients with SSc or mixed connective tissue disease, 13 percent had an elevated right ventricular systolic pressure (an indicator of PAH) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/10\">",
"       10",
"      </a>",
"      ]. In another study of 227 patients with SSc, serial Doppler echocardiograms found a high tricuspid gradient (also an indicator of PAH) in 11 percent of patients during the initial echocardiogram and 17 percent during a subsequent echocardiogram [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20567?source=see_link&amp;anchor=H17589936#H17589936\">",
"       \"Echocardiographic evaluation of the pulmonic valve and pulmonary artery\", section on 'Pulmonary hemodynamics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exercise echocardiography &ndash; A study of 54 patients with SSc found that 44 percent had an abnormal response to exercise (defined as a &ge;20 mmHg increase of the estimated pulmonary arterial systolic pressure (PASP) during exercise, as measured echocardiographically) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/8\">",
"       8",
"      </a>",
"      ]. Right heart catheterization confirmed the presence of resting or exercise induced PAH in 81 percent of these patients. Thus, resting PAH was identified in nearly 36 percent of the study population. Of note, the abnormal response to exercise strongly correlated with a very low diffusion capacity (DLCO) and a high forced vital capacity to DLCO ratio",
"      <span class=\"nowrap\">",
"       (FVC/DLCO).",
"      </span>",
"      Among 164 with SSc and a normal resting PASP, 42 percent had a significant increase in PASP with exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/12\">",
"       12",
"      </a>",
"      ]. A peak exercise PASP of &ge;50 mmHg (6.65 kPa) was associated with greater age, interstitial lung disease, and right and left ventricular diastolic dysfunction, suggesting multiple potential etiologies for exercise-induced increases in PASP in SSc and supporting the need for right heart catheterization to clarify the finding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41048?source=see_link&amp;anchor=H7#H7\">",
"       \"Stress echocardiography: Indications, imaging techniques and safety\", section on 'Doppler stress echocardiography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diagnostic algorithms &ndash; A study of 709 patients who had SSc identified PAH in 8 percent of the patients using an algorithm that included Doppler echocardiography and right heart catheterization [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, the studies have estimated that the prevalence of PAH is 8 to 37 percent among patients with SSc who have never been diagnosed with pulmonary vascular disease range [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/8,10,11,13\">",
"     8,10,11,13",
"    </a>",
"    ]. This high prevalence, combined with the high mortality rate of SSc-associated PAH and the observation that early detection of milder disease is associated with better survival [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/9,14\">",
"     9,14",
"    </a>",
"    ], has been used as an argument to screen patients who have SSc for PAH.",
"   </p>",
"   <p>",
"    These factors must be weighed against the potential pitfalls of screening, which include the impact of false positive and false negative results. False positive results may lead to unnecessary right heart catheterization and related complications, as well as unnecessary patient anxiety. False negative results may lead to false reassurance and decreased vigilance in the clinical assessment of symptoms and signs of PAH, ultimately delaying diagnosis and therapy. False positive and false negative results are most common among patients who have interstitial lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We believe that all patients with SSc should be monitored for the development of PAH as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be evaluated regularly and thoroughly for symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs of PAH. The symptoms and signs of PAH are described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of pulmonary hypertension in adults\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients should have a baseline and yearly pulmonary function tests (PFTs) to look for changes in the diffusion capacity (DLCO) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Patients who have no dyspnea or exercise intolerance, and who have had a persistently normal DLCO over ten years of disease, may have the frequency of their PFTs decreased to every two years [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients should have an echocardiogram performed every two years [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A diagnostic evaluation should be initiated if any symptoms or signs of pulmonary vascular disease develop, the DLCO is reduced (&lt;70 percent of predicted), the DLCO is decreased disproportionately to the FVC (ie, FVC",
"    <span class=\"nowrap\">",
"     percent/DLCO",
"    </span>",
"    percent &gt;1.6), or an echocardiogram has evidence of pulmonary vascular disease (eg, right ventricular dysfunction, an elevated tricuspid regurgitant velocity, or an increased estimated pulmonary arterial systolic pressure). The diagnostic evaluation of suspected SSc-associated PAH is the same as that for other types of PAH, which is discussed in detail elsewhere. Suspected SSc-associated PAH should not be treated without first performing a right heart catheterization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary arterial hypertension (PAH) is an independent risk factor for mortality among patients with systemic sclerosis (SSc) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/18\">",
"     18",
"    </a>",
"    ]. The severity of the PAH and the presence of coexisting interstitial lung disease (ILD) directly correlate with mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/9,19-21\">",
"     9,19-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective cohort study of 794 patients with SSc found a prevalence of PAH of 12 percent, which was confirmed by right heart catheterization [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/20\">",
"       20",
"      </a>",
"      ]. The two year mortality rates among patients with mean pulmonary artery pressures of &lt;32 mmHg and &gt;45 mmHg were 22 and 61 percent, respectively. A high right atrial pressure (indicative of right ventricular failure) was the strongest hemodynamic predictor of mortality.",
"     </li>",
"     <li>",
"      A prospective cohort study of 59 patients with SSc and pulmonary hypertension (confirmed by right heart catheterization) compared patients with coexisting ILD to patients without ILD [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/21\">",
"       21",
"      </a>",
"      ]. Survival was significantly worse among patients with coexisting ILD (46 versus 79 percent). Most of the deaths among the patients with ILD were due to respiratory failure, whereas most of the deaths among patients without ILD were due to right heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/21\">",
"       21",
"      </a>",
"      ]. These findings were supported by a subsequent retrospective cohort study of 97 patients, which found that patients with SSc-associated ILD and pulmonary hypertension (confirmed by right heart catheterization) had a worse three-year survival than patients with SSc-associated PAH (47 versus 71 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Progression of SSc-associated PAH is not inevitable. In one observational study of patients with SSc, 30 percent of those who had an estimated pulmonary artery pressure of &gt;30 mmHg on an echocardiogram were found to have an estimated pulmonary artery pressure &lt;30 mmHg two years later.",
"   </p>",
"   <p>",
"    The prognosis for patients with SSc-associated PAH is worse than that for patients with idiopathic pulmonary arterial hypertension (IPAH). This was suggested by a retrospective cohort study of 91 patients that found that patients with SSc-associated PAH had one-, two-, and three-year survival rates of 87, 64, and 64 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/23\">",
"     23",
"    </a>",
"    ]. In contrast, patients with IPAH had one-, two-, and three-year survival rates of 91, 88, and 78 percent, respectively. Patients with SSc-associated PAH also had higher serum levels of N-terminal brain natriuretic peptide (NT-BNP) than patients with IPAH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. NT-BNP is an index of cardiac strain.",
"   </p>",
"   <p>",
"    Survival among patients with SSc-associated PAH appears to have improved modestly over the past decade. This is most likely the consequence of earlier diagnosis and more effective supportive and directed therapies. A prospective cohort study of 92 patients with SSc-associated PAH (confirmed by right heart catheterization) compared the survival of patients prior to 2002 with that of patients in the current treatment era [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6935/abstract/25\">",
"     25",
"    </a>",
"    ]. Two year survival was significantly better in the current era (71 versus 47 percent). Therapy generally consisted of diuretics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , oxygen,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , and prostanoids prior to 2002, but the endothelin-1 antagonists became the most frequently used first-line therapy during the current era.",
"   </p>",
"   <p>",
"    Despite its improvement, the mortality rate of SSc-associated PAH remains unacceptably high, particularly when associated with ILD. Treatment of SSc-associated PAH is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26342?source=see_link\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary hypertension is a common and serious complication of systemic sclerosis (SSc). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary hypertension is classified into five groups by the World Health Organization (WHO) (",
"      <a class=\"graphic graphic_table graphicRef66348 \" href=\"UTD.htm?42/38/43628\">",
"       table 1",
"      </a>",
"      ). SSc can be associated with group 1 pulmonary arterial hypertension (PAH) or group 3 pulmonary hypertension (PH) secondary to interstitial lung disease. In addition, patients with SSc frequently have diastolic dysfunction and group 2 PH. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SSc-associated PAH is defined as a mean pulmonary artery pressure greater than 25 mmHg at rest (measured by right heart catheterization), with a wedge pressure less than or equal to 15 mmHg in a patient who has SSc without significant coexisting interstitial lung disease causing chronic hypoxia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for PAH among patients with SSc include the following: long-standing limited cutaneous SSc with a positive anti-centromere antibody, numerous cutaneous telangiectasia, diffuse cutaneous SSc associated with a nucleolar pattern of antinuclear antibody (ANA), an isolated decrease in the diffusion capacity (DLCO) less than 60 percent predicted or a progressive decrease of the diffusion capacity (DLCO), and exercise-induced PH on right heart catheterization. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Estimates of the prevalence of unrecognized PAH among patients with SSc range from 8 to 37 percent. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We believe that all patients with SSc should be evaluated regularly and thoroughly for symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs of PAH, as well as having regular pulmonary function tests (PFTs) to look for changes in the diffusion capacity (DLCO). We do not advocate routine screening for PAH in patients who do not have pulmonary symptoms and who have a normal DLCO. However, yearly PFTs and echocardiograms should be considered if the DLCO is decreased (&lt;70 percent of predicted). Clinicians should maintain a low threshold to initiate a diagnostic evaluation if any symptoms or signs of pulmonary vascular disease develop. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PAH is an independent risk factor for mortality among patients with SSc. The severity of the PAH and the presence of coexisting interstitial lung disease each directly correlate with mortality. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/1\">",
"      Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/2\">",
"      Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/3\">",
"      Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/4\">",
"      Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/5\">",
"      Shah AA, Wigley FM, Hummers LK. Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension. J Rheumatol 2010; 37:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/6\">",
"      Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/7\">",
"      Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/8\">",
"      Steen V, Chou M, Shanmugam V, et al. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. Chest 2008; 134:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/9\">",
"      Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/10\">",
"      Wigley FM, Lima JA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005; 52:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/11\">",
"      Hesselstrand R, Ekman R, Eskilsson J, et al. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology (Oxford) 2005; 44:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/12\">",
"      Gargani L, Pignone A, Agoston G, et al. Clinical and echocardiographic correlations of exercise-induced pulmonary hypertension in systemic sclerosis: a multicenter study. Am Heart J 2013; 165:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/13\">",
"      Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52:3792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/14\">",
"      Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63:3522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/15\">",
"      Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/16\">",
"      Schreiber BE, Valerio CJ, Keir GJ, et al. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis Rheum 2011; 63:3531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/17\">",
"      Fischer A, Bull TM, Steen VD. Practical approach to screening for scleroderma-associated pulmonary arterial hypertension. Arthritis Care Res (Hoboken) 2012; 64:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/18\">",
"      Hachulla E, Carpentier P, Gressin V, et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French Itin&eacute;rAIR-Scl&eacute;rodermie study. Rheumatology (Oxford) 2009; 48:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/19\">",
"      MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/20\">",
"      Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/21\">",
"      Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/22\">",
"      Launay D, Humbert M, Berezne A, et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest 2011; 140:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/23\">",
"      Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54:3043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/24\">",
"      Mathai SC, Bueso M, Hummers LK, et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 2010; 35:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6935/abstract/25\">",
"      Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006; 92:926.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8251 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_49_6935=[""].join("\n");
var outline_f6_49_6935=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/8251\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8251|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/38/43628\" title=\"table 1\">",
"      WHO pulmonary hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26329?source=related_link\">",
"      Clinical manifestations of systemic sclerosis (scleroderma) lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20567?source=related_link\">",
"      Echocardiographic evaluation of the pulmonic valve and pulmonary artery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/19/7482?source=related_link\">",
"      Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16889?source=related_link\">",
"      Pulmonary hypertension associated with interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26342?source=related_link\">",
"      Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41048?source=related_link\">",
"      Stress echocardiography: Indications, imaging techniques and safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_49_6936="Subdural hematoma in adults: Etiology, clinical features, and diagnosis";
var content_f6_49_6936=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Subdural hematoma in adults: Etiology, clinical features, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/49/6936/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6936/contributors\">",
"     William McBride, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/49/6936/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6936/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/49/6936/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6936/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/49/6936/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subdural hematoma (SDH) and epidural hematoma are characterized by bleeding into the spaces surrounding the brain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subdural hematomas form between the dura and the arachnoid membranes",
"     </li>",
"     <li>",
"      Epidural hematomas arise in the potential space between the dura and the skull",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathophysiology, etiology, clinical features, and diagnostic evaluation of SDH will be discussed here. Treatment of SDH is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43767?source=see_link\">",
"     \"Subdural hematoma in adults: Prognosis and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epidural hematoma is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19112?source=see_link\">",
"     \"Intracranial epidural hematoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of closed head injury, the linear translation of acceleration along the diameter of the skull in the lateral direction can produce injury to veins, arteries, or brain parenchyma, resulting in SDH, epidural hematoma, or coup-countercoup contusions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute SDH is usually caused by tearing of the bridging veins that drain from the surface of the brain to the dural sinuses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/2\">",
"     2",
"    </a>",
"    ]. Rupture of these vessels allows for bleeding into the space between the arachnoid membranes and dura through which the vessels traverse. Venous bleeding is usually arrested by the rising intracranial pressure or direct compression by the clot itself.",
"   </p>",
"   <p>",
"    Arterial rupture can also result in SDH, and this source accounts for approximately 20 to 30 percent of SDH cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In an autopsy study of 46 patients with isolated SDH that included 23 caused by bridging vein rupture and 23 caused by arterial injury, most of the arterial SDHs were caused by injuries to small cortical arteries of &lt;1 mm diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/5\">",
"     5",
"    </a>",
"    ]. Both arterial and venous SDHs had generally similar postmortem characteristics, although SDHs caused by arterial rupture were predominately located in the temporoparietal region, while those caused by bridging vein rupture were predominately frontoparietal.",
"   </p>",
"   <p>",
"    Low cerebrospinal fluid (CSF) pressure (intracranial hypotension) is another mechanism that can result in SDH. Intracranial hypotension is typically caused by a spontaneous or iatrogenic cerebrospinal fluid leak, as may occur following lumbar puncture. As the cerebrospinal fluid pressure decreases, there is a reduction in the buoyancy of the brain, causing traction on the anchoring and supporting structures. Traction on bridging veins can cause tearing and rupture of these vessels, while intracranial hypotension itself leads to engorgement of cerebral veins and subsequent leakage of fluid into the subdural space. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Key differences between SDH and epidural hematoma are readily demonstrable by unenhanced head CT or by pathologic specimens. Epidural hematoma does not cross sutural margins, but does cross dural attachments because it is located in the potential space between dura and skull. As a consequence of this, epidural hematoma characteristically has a lens-shaped appearance. SDH can cross sutural margins, but is limited by dural attachments and therefore typically appears as a crescent-shaped extra-axial lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Development of chronic subdural hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the initial meningeal trauma and development of SDH, dural collagen synthesis is induced and fibroblasts spread over the inner surface of the dura to form a thick outer membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Subsequently, a thinner inner membrane develops, resulting in complete encapsulation of the clot. This occurs over a predictable time course of approximately two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over time, a chronic SDH may liquefy to form a hygroma, and the membranes may calcify [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/7\">",
"     7",
"    </a>",
"    ]. More than one-half of all SDHs liquefy and tend to enlarge as opposed to remaining solid and stable in size [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/2\">",
"     2",
"    </a>",
"    ]. Although the reason for this observation is unknown, a larger initial clot size appears to be related to a greater likelihood of subsequent expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At any time, the hematoma may expand secondary to recurrent bleeding (\"acute-on-chronic\" SDH) or from osmotic draw of water into the hygroma, owing to its high protein content. Thalamic lesions and secondary brainstem injury may develop as a consequence of the mass effect produced by a large SDH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Subdural hygroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to forming as the result of SDH degeneration, subdural hygromas are thought to develop passively as a consequence of traumatic brain injury followed by brain atrophy, dehydration, or decreased intracranial pressure. The mechanism of hygroma formation in this setting is related to the separation of the arachnoid layer from the dura, which can occur when a contracting brain pulls the arachnoid along with it while the dura remains adherent to the skull [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most subdural hygromas will resolve with adequate reexpansion of the intracranial contents (ie, hydration). However, some will become chronic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/9\">",
"     9",
"    </a>",
"    ]. The persistence of hygromas appears to be related to the formation of pseudomembranes (as discussed above) that line the space created between the arachnoid and the dura during the acute phase. These subsequently become vascularized by abnormally permeable capillaries that allow for further accumulation of subdural fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head trauma is the most common cause of SDH, with the majority of cases related to motor vehicle accidents, falls, and assaults [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with significant cerebral atrophy are at high risk for SDH. This category includes the elderly, those with a history of chronic alcohol abuse, and those with previous traumatic brain injury. In such patients, trivial head trauma or even pure whiplash injury in the absence of physical impact may produce an SDH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. Thus, SDH, particularly chronic SDH, is seen in older adults more commonly than younger adults. However, when limited to acute SDH cases caused by mild to severe head injuries, the mean age of affected patients is between 31 and 47 years old, and the majority are men [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/10,12-15\">",
"     10,12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the exact incidence of SDH is unknown, acute SDH complicates approximately 11 percent of mild to severe head injuries that require hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/10,14,15\">",
"     10,14,15",
"    </a>",
"    ], and approximately 20 percent of severe traumatic brain injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/10,16-19\">",
"     10,16-19",
"    </a>",
"    ]. One series of neurointensive care unit admissions reported 31 patients with SDH and seven patients with epidural hematoma over a 10 month period [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/20\">",
"     20",
"    </a>",
"    ], suggesting that SDH is more common than epidural hematoma.",
"   </p>",
"   <p>",
"    The use of antithrombotic agents increases the risk of SDH, as illustrated by the following reports.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of patients with chronic SDH following head trauma, treatment with oral anticoagulants,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      at the time of hemorrhage was present in 21, 13, and 5 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case-control analysis compared 121 consecutive adults who developed intracranial hemorrhage while taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (including 44 with SDH) with 363 matched controls managed by the outpatient anticoagulation clinic [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/22\">",
"       22",
"      </a>",
"      ]. The risk of SDH was significantly associated with a prothrombin time ratio of &gt;2, approximately equivalent to an international normalized ratio (INR) &gt;4.0.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Spontaneous SDH refers to hemorrhage occurring in the absence of provoking factors such as diffuse cerebral atrophy, head trauma, or anticoagulation. In one review reporting 116 surgical cases of acute SDH, spontaneous SDH accounted for 2.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/23\">",
"     23",
"    </a>",
"    ]. Such hemorrhages typically occur due to rupture of a cortical branch of the middle cerebral artery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Unusual causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unusual causes of SDH include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SDH accompanies 0.5 to 7.9 percent of aneurysmal subarachnoid hemorrhages [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/25-29\">",
"       25-29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rarely, aneurysm rupture causes isolated SDH without subarachnoid hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/29\">",
"       29",
"      </a>",
"      ]. One report described a patient who developed a spontaneous occipital SDH without subarachnoid hemorrhage due to rupture of an internal carotid artery aneurysm that was adherent to the arachnoid membrane, perhaps because of previous minor hemorrhages [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SDH can occur from bleeding due to other underlying disorders, including the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Arteriovenous malformation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/31\">",
"       31",
"      </a>",
"      ] (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=see_link\">",
"       \"Brain arteriovenous malformations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Meningioma [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/32\">",
"       32",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=see_link\">",
"       \"Meningioma: Clinical presentation and diagnosis\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Dural metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/33-35\">",
"       33-35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Coagulopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/36\">",
"       36",
"      </a>",
"      ]&nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"       \"Approach to the adult patient with a bleeding diathesis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SDH is sometimes seen in neonates and children as a result of inflicted head trauma from child abuse. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link&amp;anchor=H7#H7\">",
"       \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\", section on 'Intracranial bleeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      SDH may complicate systemic thrombolysis for acute myocardial infarction, although the incidence is quite low. One trial reported that treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , and intravenous recombinant tissue-type plasminogen activator (rt-PA) at doses of 150 mg or 100 mg was complicated by SDH in 0.2 and 0.1 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/37\">",
"       37",
"      </a>",
"      ]. Another study found that SDH in patients receiving rt-PA for acute myocardial infarction was generally associated with a history of preexisting head trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SDH can occur with spontaneous cerebrospinal fluid hypotension or following procedures complicated by a persistent cerebrospinal fluid leak, such as lumbar puncture, ventriculostomy, or lumboperitoneal shunt placement. The risk of cerebrospinal hypotension-induced SDH may be increased in patients with thrombocytopenia and in those receiving chemotherapy for leukemia [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=see_link\">",
"       \"Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14762?source=see_link&amp;anchor=H24#H24\">",
"       \"Normal pressure hydrocephalus\", section on 'Shunt complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      SDH may complicate neurosurgical procedures.",
"     </li>",
"     <li>",
"      Cocaine abuse with associated hypertension and vasospasm has been proposed as a rare cause of spontaneous SDH [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial presentation of SDH has a spectrum of manifestations. Severe head trauma may result in SDH with coma, while a lesser injury may produce acute SDH with only momentary loss of consciousness. Subacute and chronic SDH may present insidiously, typically with disturbances of consciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The categories of acute, subacute, and chronic SDH are arbitrarily defined by time from onset, but there is no consensus in the literature regarding these definitions. For this discussion, we define these categories as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute SDH presents one to two days after onset",
"     </li>",
"     <li>",
"      Subacute SDH presents 3 to 14 days after onset",
"     </li>",
"     <li>",
"      Chronic SDH presents 15 or more days after onset",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These definitions are less useful when there is no history of trauma or inciting event prior to the clinical presentation of SDH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acute subdural hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following an acute SDH, coma is present from the time of injury in approximately 50 percent of cases. However, approximately 12 to 38 percent of patients have a transient \"lucid interval\" after the acute injury that is followed by a progressive neurologic decline to coma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. Posterior fossa SDH, like most space-occupying lesions in this location, presents with symptoms of elevated intracranial pressure including headache, vomiting, anisocoria, dysphagia, cranial nerve palsies, nuchal rigidity, and ataxia.",
"   </p>",
"   <p>",
"    In some instances of SDH, cerebral hypoperfusion due to increased intracranial pressure or mass effect may culminate in cerebral infarction. This is especially true in the posterior fossa, where the posterior cerebral arteries are vulnerable to compression along the edge of the tentorium cerebelli [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/42\">",
"     42",
"    </a>",
"    ]. A presentation characteristic of the Kluver-Bucy syndrome (placidity with loss of normal fear and anger, aberrant sexual behavior, excessive oral tendencies, and increased appetite) has been described after acute SDH complicated by herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chronic subdural hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insidious onset of headaches, light-headedness, cognitive impairment, apathy, somnolence, and occasionally seizures, may occur as a consequence of chronic SDH, and symptoms may not become evident until weeks after the initial injury. Global deficits such as disturbances of consciousness are more common than focal deficits after SDH.",
"   </p>",
"   <p>",
"    Focal deficits may be either ipsilateral or contralateral to the side of the SDH. Contralateral hemiparesis can occur as a result of direct compression of cortex underlying the hematoma, whereas ipsilateral hemiparesis can occur with lateral displacement of the midbrain caused by the mass effect of the hematoma. Such midbrain displacement results in compression of the contralateral cerebral peduncle against the free edge of the tentorium [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/2\">",
"     2",
"    </a>",
"    ]. Symptoms due to chronic SDH may be transient or fluctuating [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bitemporal chronic SDH may present with intermittent paraparesis that is proximal and painless [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of acute head trauma, imaging serves a key role in both the diagnosis of specific injury as well as the determination of appropriate initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to SDH, head trauma is a major cause of epidural hematoma (EDH), subarachnoid hemorrhage, cerebral contusion, diffuse brain swelling, and fractures. Any of these injuries may coexist in a given patient following trauma, and their clinical manifestations can be difficult to distinguish [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/2,10,14,15\">",
"     2,10,14,15",
"    </a>",
"    ]. However, it is important to identify the specific nature of the lesion during initial evaluation, as potentially life-saving treatment will differ accordingly.",
"   </p>",
"   <p>",
"    Lumbar puncture is contraindicated due to the risk of herniation in any case where a space-occupying lesion such as a SDH is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Head CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) of the head is the most widely used imaging study for acute head trauma owing to its speed, relative simplicity, and widespread availability [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute SDH is readily visualized on head CT as a high-density crescentic collection across the hemispheric convexity (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68424 \" href=\"UTD.htm?8/29/8656\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Subacute and chronic SDH appear as isodense or hypodense crescent-shaped lesions (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80783 \" href=\"UTD.htm?19/16/19713\">",
"       image 2",
"      </a>",
"      ) that deform the surface of the brain [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/7\">",
"       7",
"      </a>",
"      ]. Their associated membranes may enhance with intravenous contrast.",
"     </li>",
"     <li>",
"      In contrast to SDH, epidural blood produces a convex pattern on CT because its collection is limited by firm dural attachments at the cranial sutures [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/7\">",
"       7",
"      </a>",
"      ]. (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60726 \" href=\"UTD.htm?3/40/3716\">",
"       image 3",
"      </a>",
"      ). Epidural hematoma is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19112?source=see_link\">",
"       \"Intracranial epidural hematoma in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study published in 1988, approximately 91 percent of SDHs &ge;5 mm in thickness were identified on initial head CT [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/46\">",
"     46",
"    </a>",
"    ]. In contrast, SDHs &le;3 mm in thickness were often missed initially but noted to be present retrospectively. With improvements in resolution, modern generation CT scanners may provide even greater sensitivity for the detection of SDH than that demonstrated in the 1988 study. However, there have been no published data to confirm this impression.",
"   </p>",
"   <p>",
"    Unilateral SDH with mass effect will generate a fairly obvious distortion of anatomy on CT. However, bilateral SDH may be easily missed, as the brain parenchyma will appear symmetric, while the clots themselves may be isointense relative to brain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Brain MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although head CT is more widely used, brain MRI is more sensitive than head CT for the detection of intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/46\">",
"     46",
"    </a>",
"    ]. MRI is also more sensitive for the detection of small SDH, and tentorial and interhemispheric SDH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/46\">",
"     46",
"    </a>",
"    ]. As an example, in an early study that included 39 patients with SDH, the sensitivities for the detection of extra-axial hematomas (SDH and epidural hematoma) using T1-weighted MR, T2-weighted MR, and head CT were 97, 89, and 71 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most centers, brain magnetic resonance imaging (MRI) is used for situations in which there is suspicion for SDH or other intracranial hemorrhage, but no clear evidence of hematoma by CT.",
"   </p>",
"   <p>",
"    The MRI signal appearance of SDH and epidural hematoma evolves over time in a manner similar to that observed in parenchymal hematoma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50871 \" href=\"UTD.htm?10/52/11074\">",
"     image 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The acute clot is hypointense on T2-weighted images due to the presence of deoxyhemoglobin.",
"     </li>",
"     <li>",
"      Over subsequent weeks, deoxyhemoglobin degrades to methemoglobin, which appears bright on both T1 and T2-weighted images.",
"     </li>",
"     <li>",
"      At several months, only hemosiderin remains, and the clot again becomes hypointense on the T1-weighted images.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under some conditions, noninvasive angiography (eg, MRA or CTA) or conventional cerebral angiography may be indicated for evaluation of SDH, particularly when there is no history of trauma and no obvious cause [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/29\">",
"     29",
"    </a>",
"    ]. As an example, spontaneous SDH can rarely occur as a consequence of intracranial aneurysmal rupture, and angiography may be necessary to fully evaluate the possibility of an underlying vascular lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/47\">",
"     47",
"    </a>",
"    ]. Thus, conventional angiography should be considered if there is suspicion for an underlying vascular lesion and the source of bleeding is not detected by noninvasive MRA or CTA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/14/24801?source=see_link\">",
"       \"Patient information: Subdural hematoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subdural hematoma (SDH) is caused by bleeding in the potential space between the dura and the arachnoid membranes. Most cases of SDH result from tearing of the bridging veins that drain from the surface of the brain to the dural sinuses, but arterial rupture accounts for approximately 20 to 30 percent of cases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Head trauma is the most common cause of SDH, with the majority of cases related to motor vehicle accidents, falls, and assaults [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6936/abstract/10\">",
"       10",
"      </a>",
"      ]. The incidence of acute traumatic SDH is highest among middle-aged men. However, patients with significant cerebral atrophy (the elderly, those with a history of chronic alcohol abuse, and those with previous traumatic brain injury) are at high risk for SDH, and the overall incidence of SDH is highest among older adults. The use of antithrombotic agents increases the risk of SDH. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology and etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unusual causes of SDH include bleeding from a variety of sources (aneurysm, arteriovenous malformation, meningioma, dural metastases, coagulopathy) and cerebrospinal fluid hypotension. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Unusual causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coma is present from the time of injury in approximately 50 percent of acute SDH cases. However, up to 38 percent of patients have a transient \"lucid interval\" that is followed by a progressive neurologic decline to coma. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Acute subdural hematoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic SDH may present with the insidious onset of headaches, light-headedness, cognitive impairment, apathy, somnolence, and occasionally seizures. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chronic subdural hematoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to SDH, head trauma is a major cause of epidural hematoma (EDH), subarachnoid hemorrhage, cerebral contusion, diffuse brain swelling, and fractures. Any of these injuries may coexist in a given patient following trauma, and their clinical manifestations can be difficult to distinguish. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computed tomography (CT) of the head is the most widely used imaging study for acute head trauma owing to its speed, accuracy, and widespread availability. Acute SDH is visualized on CT as a high-density crescentic collection across the hemispheric convexity. However, brain MRI is more sensitive than CT for the detection of SDH, particularly for hematomas that are small, or those located adjacent to the tentorium cerebelli or interhemispheric fissure. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30801974\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. David Brock, who contributed to an earlier version of this topic.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/1\">",
"      Besenski N. Traumatic injuries: imaging of head injuries. Eur Radiol 2002; 12:1237.",
"     </a>",
"    </li>",
"    <li>",
"     Victor M, Ropper A. Craniocerebral trauma. In: Adams and Victor's Principles of Neurology, 7th ed, Victor M, Ropper A.  (Eds), McGraw-Hill, New York 2001. p.925.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/3\">",
"      Gennarelli TA, Thibault LE. Biomechanics of acute subdural hematoma. J Trauma 1982; 22:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/4\">",
"      Haselsberger K, Pucher R, Auer LM. Prognosis after acute subdural or epidural haemorrhage. Acta Neurochir (Wien) 1988; 90:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/5\">",
"      Maxeiner H, Wolff M. Pure subdural hematomas: a postmortem analysis of their form and bleeding points. Neurosurgery 2002; 50:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/6\">",
"      Sajanti J, Majamaa K. High concentrations of procollagen propeptides in chronic subdural haematoma and effusion. J Neurol Neurosurg Psychiatry 2003; 74:522.",
"     </a>",
"    </li>",
"    <li>",
"     Mayer S, Rowland L. Head injury. In: Merritt's Neurology, Rowland L.  (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2000. p.401.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/8\">",
"      Labadie EL, Glover D. Physiopathogenesis of subdural hematomas. Part 1: Histological and biochemical comparisons of subcutaneous hematoma in rats with subdural hematoma in man. J Neurosurg 1976; 45:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/9\">",
"      Lee KS. The pathogenesis and clinical significance of traumatic subdural hygroma. Brain Inj 1998; 12:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/10\">",
"      Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of acute subdural hematomas. Neurosurgery 2006; 58:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/11\">",
"      Doherty DL. Posttraumatic cerebral atrophy as a risk factor for delayed acute subdural hemorrhage. Arch Phys Med Rehabil 1988; 69:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/12\">",
"      Dent DL, Croce MA, Menke PG, et al. Prognostic factors after acute subdural hematoma. J Trauma 1995; 39:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/13\">",
"      Ko&ccedil; RK, Akdemir H, Oktem IS, et al. Acute subdural hematoma: outcome and outcome prediction. Neurosurg Rev 1997; 20:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/14\">",
"      Massaro F, Lanotte M, Faccani G, Triolo C. One hundred and twenty-seven cases of acute subdural haematoma operated on. Correlation between CT scan findings and outcome. Acta Neurochir (Wien) 1996; 138:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/15\">",
"      Servadei F, Nasi MT, Giuliani G, et al. CT prognostic factors in acute subdural haematomas: the value of the 'worst' CT scan. Br J Neurosurg 2000; 14:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/16\">",
"      Seelig JM, Becker DP, Miller JD, et al. Traumatic acute subdural hematoma: major mortality reduction in comatose patients treated within four hours. N Engl J Med 1981; 304:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/17\">",
"      Ersahin Y, Mutluer S. Posterior fossa extradural hematomas in children. Pediatr Neurosurg 1993; 19:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/18\">",
"      Wilberger JE Jr, Harris M, Diamond DL. Acute subdural hematoma: morbidity, mortality, and operative timing. J Neurosurg 1991; 74:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/19\">",
"      Servadei F, Nasi MT, Cremonini AM, et al. Importance of a reliable admission Glasgow Coma Scale score for determining the need for evacuation of posttraumatic subdural hematomas: a prospective study of 65 patients. J Trauma 1998; 44:868.",
"     </a>",
"    </li>",
"    <li>",
"     Ropper A. Introduction to critical care in neurology and neurosurgery. In: Neurological and Neurosurgical Intensive Care, Ropper A, Kennedy S, Zervas N.  (Eds), University Park Press, Baltimore 1983. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/21\">",
"      Reymond MA, Marbet G, Rad&uuml; EW, Gratzl O. Aspirin as a risk factor for hemorrhage in patients with head injuries. Neurosurg Rev 1992; 15:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/22\">",
"      Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/23\">",
"      Komatsu Y, Uemura K, Yasuda S, et al. [Acute subdural hemorrhage of arterial origin: report of three cases]. No Shinkei Geka 1997; 25:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/24\">",
"      Ishii T, Sawauchi S, Taya K, et al. [Acute spontaneous subdural hematoma of arterial origin]. No Shinkei Geka 2004; 32:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/25\">",
"      Barton E, Tudor J. Subdural haematoma in association with intracranial aneurysm. Neuroradiology 1982; 23:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/26\">",
"      Nowak G, Schwachenwald S, Kehler U, et al. Acute subdural haematoma from ruptured intracranial aneurysms. Acta Neurochir (Wien) 1995; 136:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/27\">",
"      Inamasu J, Saito R, Nakamura Y, et al. Acute subdural hematoma caused by ruptured cerebral aneurysms: diagnostic and therapeutic pitfalls. Resuscitation 2002; 52:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/28\">",
"      Gelabert-Gonzalez M, Iglesias-Pais M, Fern&aacute;ndez-Villa J. Acute subdural haematoma due to ruptured intracranial aneurysms. Neurosurg Rev 2004; 27:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/29\">",
"      Koerbel A, Ernemann U, Freudenstein D. Acute subdural haematoma without subarachnoid haemorrhage caused by rupture of an internal carotid artery bifurcation aneurysm: case report and review of literature. Br J Radiol 2005; 78:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/30\">",
"      Utsunomiya A, Narita N. Spontaneous occipital subdural haematoma. J Neurol Neurosurg Psychiatry 2001; 71:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/31\">",
"      Rengachary SS, Szymanski DC. Subdural hematomas of arterial origin. Neurosurgery 1981; 8:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/32\">",
"      Okuno S, Touho H, Ohnishi H, Karasawa J. Falx meningioma presenting as acute subdural hematoma: case report. Surg Neurol 1999; 52:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/33\">",
"      Bergmann M, Puskas Z, Kuchelmeister K. Subdural hematoma due to dural metastasis: case report and review of the literature. Clin Neurol Neurosurg 1992; 94:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/34\">",
"      Laigle-Donadey F, Taillibert S, Mokhtari K, et al. Dural metastases. J Neurooncol 2005; 75:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/35\">",
"      Ishii N, Yokosuka K, Sekihara Y, et al. [A case of subdural hematoma associated with dural metastasis of lung cancer]. No Shinkei Geka 2007; 35:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/36\">",
"      Se&ccedil;kin H, Kazanci A, Yigitkanli K, et al. Chronic subdural hematoma in patients with idiopathic thrombocytopenic purpura: A case report and review of the literature. Surg Neurol 2006; 66:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/37\">",
"      Gore JM, Sloan M, Price TR, et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. Circulation 1991; 83:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/38\">",
"      Gebel JM, Sila CA, Sloan MA, et al. Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Stroke 1998; 29:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/39\">",
"      Ezri T, Abouleish E, Lee C, Evron S. Intracranial subdural hematoma following dural puncture in a parturient with HELLP syndrome. Can J Anaesth 2002; 49:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/40\">",
"      Jourdan E, Dombret H, Glaisner S, et al. Unexpected high incidence of intracranial subdural haematoma during intensive chemotherapy for acute myeloid leukaemia with a monoblastic component. Br J Haematol 1995; 89:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/41\">",
"      Alves OL, Gomes O. Cocaine-related acute subdural hematoma: an emergent cause of cerebrovascular accident. Acta Neurochir (Wien) 2000; 142:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/42\">",
"      Yoneoka Y, Takeda N, Inoue A, et al. Human Kluver-Bucy syndrome following acute subdural haematoma. Acta Neurochir (Wien) 2004; 146:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/43\">",
"      Kaminski HJ, Hlavin ML, Likavec MJ, Schmidley JW. Transient neurologic deficit caused by chronic subdural hematoma. Am J Med 1992; 92:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/44\">",
"      Schaller B, Radziwill AJ, Wasner M, et al. [Intermittent paraparesis as manifestation of a bilateral chronic subdural hematoma]. Schweiz Med Wochenschr 1999; 129:1067.",
"     </a>",
"    </li>",
"    <li>",
"     Grossman RI. Head Trauma. In: Neuroradiology: The Requisites, 2nd ed, Mosby, Philadelphia 2003. p.243.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/46\">",
"      Gentry LR, Godersky JC, Thompson B, Dunn VD. Prospective comparative study of intermediate-field MR and CT in the evaluation of closed head trauma. AJR Am J Roentgenol 1988; 150:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6936/abstract/47\">",
"      Nonaka Y, Kusumoto M, Mori K, Maeda M. Pure acute subdural haematoma without subarachnoid haemorrhage caused by rupture of internal carotid artery aneurysm. Acta Neurochir (Wien) 2000; 142:941.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1105 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_49_6936=[""].join("\n");
var outline_f6_49_6936=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Development of chronic subdural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Subdural hygroma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Unusual causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acute subdural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chronic subdural hematoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Head CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Brain MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30801974\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1105\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1105|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/29/8656\" title=\"diagnostic image 1\">",
"      CT Bilateral traumatic SDH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/16/19713\" title=\"diagnostic image 2\">",
"      CT Subacute subdural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/40/3716\" title=\"diagnostic image 3\">",
"      CT acute traumatic epidural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/52/11074\" title=\"diagnostic image 4\">",
"      MRI subdural hematoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=related_link\">",
"      Brain arteriovenous malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=related_link\">",
"      Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19112?source=related_link\">",
"      Intracranial epidural hematoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=related_link\">",
"      Meningioma: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14762?source=related_link\">",
"      Normal pressure hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/14/24801?source=related_link\">",
"      Patient information: Subdural hematoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43767?source=related_link\">",
"      Subdural hematoma in adults: Prognosis and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_49_6937="Uremic pruritus";
var content_f6_49_6937=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Uremic pruritus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/49/6937/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6937/contributors\">",
"     Theodore Tzeremas, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6937/contributors\">",
"     Sidney M Kobrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/49/6937/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6937/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/49/6937/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6937/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/49/6937/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H22781493\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritus is a common and bothersome symptom among patients with end-stage-renal-disease (ESRD). The pathophysiology is incompletely understood and it is often difficult to eradicate although symptoms can usually be mitigated.",
"   </p>",
"   <p>",
"    Uremic pruritus is discussed in this topic review. A general discussion of pruritus is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=see_link\">",
"     \"Pruritus: Overview of management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98332764\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported prevalence of uremic pruritus in dialysis patients has varied over the years and some studies suggest the prevalence may be decreasing with more effective dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/1\">",
"     1",
"    </a>",
"    ]. Whereas the reported prevalence between 1980 and 1993 was 50 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/2-4\">",
"     2-4",
"    </a>",
"    ], subsequent surveys note a lower rate (22 to 57 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. In one of the largest trials (the Dialysis Outcomes and Practice Patterns Study (DOPPS)), pruritus was experienced by 42 percent of dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14965810\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of uremic pruritus is poorly understood. Hypotheses implicating immunologic and opioidergic systems have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1729208\">",
"    <span class=\"h2\">",
"     Immunohypothesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunohypothesis proposes that uremic pruritus is the result of systemic inflammation rather than a local skin disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Immunomodulating therapies such as ultraviolet B phototherapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    and calcineurin inhibitors have been shown to decrease uremic pruritus in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A direct role for proinflammatory T cells and cytokines is suggested by studies that showed higher levels of proinflammatory T helper-1 (TH1) cells, C-reactive protein, interleukin-6 and interleukin-2 levels among hemodialysis patients with versus those without pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/11,15\">",
"     11,15",
"    </a>",
"    ]. Other markers of inflammation including increased white blood cell count, low albumin and high ferritin have also been associated with uremic pruritus in various studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/7,16\">",
"     7,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1729277\">",
"    <span class=\"h2\">",
"     Opioid hypothesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The opioid hypothesis proposes that imbalances in the expression of mu and kappa opioid receptors cause pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Thus, pruritus is increased by mu-receptor activation and kappa-receptor blockade, and decreased by kappa-receptor activation and mu-receptor blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/19\">",
"     19",
"    </a>",
"    ]. This hypothesis is supported by the observation that the ratio of the mu-receptor agonist (beta-endorphin) to the kappa-receptor agonist (dynorphin-A) is increased in hemodialysis patients compared with healthy controls, and this ratio increased with severity of pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22425983\">",
"    <span class=\"h2\">",
"     Other contributing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cell release of histamine and other pruritogens, and xerosis may all contribute to the pathogenesis of uremic pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/17,21,22\">",
"     17,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30440035\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No single cause underlying uremic pruritus has been identified. Multiple factors have been associated in observational studies and supportive therapies that are used to treat uremic pruritus have targeted such factors. (See",
"    <a class=\"local\" href=\"#H22781529\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following factors have been identified in multiple studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inadequate dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/6,23,24\">",
"       6,23,24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hyperparathyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elevated calcium x phosphorus product [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/6,27,28\">",
"       6,27,28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Xerosis (dry skin caused by sweat gland atrophy) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elevated serum magnesium and aluminum concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/31-33\">",
"       31-33",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less convincing associations have also been made to anemia, male gender, hypervitaminosis-A, increased beta 2 microglobulin levels, serotype HLA-B35, and comorbidities including congestive heart failure, neurologic disease, and ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/7,27,34-36\">",
"     7,27,34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk appears to be independent of age, ethnicity, type of dialysis, and underlying renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22781508\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uremic pruritus most commonly affects the back but may also involve the arms, head and abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/7,37\">",
"     7,37",
"    </a>",
"    ]. Generalized pruritus is also noted in a significant number of patients. Some patients also experience pruritus for only a few minutes each day, whereas others have it nearly continuously [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other characteristics include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms tend to be worse at night, resulting in sleep disruption [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/5-7,37,39,40\">",
"       5-7,37,39,40",
"      </a>",
"      ]. The disruption of sleep is much worse in those with more severe pruritus, possibly resulting in marked fatigue and depression [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients often report increased pruritus with heat (especially with excessive perspiration) and stress, and decreased pruritus with physical activity, cooler temperatures, and with either hot or cold showers [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients report exacerbation of pruritus during hemodialysis sessions whereas pruritus appears to lessen during hemodialysis among others [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/28,37\">",
"       28,37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical findings are limited unless there are superimposed dermatologic conditions from repetitive scratching such as excoriations, lichen simplex, pruritus nodularis, keratotic papules, and follicular hyperkeratosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/3\">",
"     3",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_picture graphicRef62257 \" href=\"UTD.htm?13/61/14296\">",
"     picture 1",
"    </a>",
"    ). Xerosis (dry skin), which is present in most patients with uremic pruritus, may not be apparent unless the skin is inspected closely when scaling and epidermal cracking may be visible [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory features may include serum blood urea nitrogen (BUN), PTH, phosphate, calcium and magnesium levels that are markedly elevated compared to dialysis patients without pruritus. Among 1773 adult hemodialysis patients who were stratified based upon the severity of pruritus, those with severe pruritus were more likely to have BUN &gt;81",
"    <span class=\"nowrap\">",
"     mg/dl",
"    </span>",
"    (odds ratio (OR) 1.4; calcium &gt;9.5",
"    <span class=\"nowrap\">",
"     mg/dl",
"    </span>",
"    (OR 1.4); phosphate 6.6",
"    <span class=\"nowrap\">",
"     mg/dl",
"    </span>",
"    (OR 1.7); and less likely to have a PTH &lt;200",
"    <span class=\"nowrap\">",
"     pg/ml)",
"    </span>",
"    (OR 0.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22781515\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since it is extremely common, we assume that pruritus presenting in dialysis patients is due to uremic pruritus unless there is unequivocal and compelling evidence of another cause. Characteristics suggestive of uremic pruritus include onset coincident with starting dialysis, persistence of symptoms, or markedly elevated",
"    <span class=\"nowrap\">",
"     calcium/phosphate,",
"    </span>",
"    PTH,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    BUN levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30440440\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant number of diseases can cause pruritus in patients with and without kidney disease. In general, a nonuremic cause of pruritus should be considered among dialysis patients with symptoms that are refractory to common treatments such as topical emollients and analgesic agents and oral antihistamines or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    . This is discussed separately (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10090?source=see_link\">",
"     \"Pruritus: Etiology and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is particularly important that the clinician consider the possibility of lymphoma, cholestasis (due to primary biliary cirrhosis or viral hepatitis for example), and hypersensitivity reactions as the cause of pruritus among dialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35400?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults\", section on 'Pruritus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\", section on 'Pruritus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23863?source=see_link\">",
"     \"Pruritus associated with cholestasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10090?source=see_link&amp;anchor=H690788#H690788\">",
"     \"Pruritus: Etiology and patient evaluation\", section on 'Dermatologic disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22781529\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;High quality evidence on which to base recommendations for the treatment of uremic pruritus is limited. Most recommendations are based on anecdotal reports and small uncontrolled clinical trials. Treatment involves a stepwise approach that depends upon the severity of symptoms and the response to initial therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H655794683\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial therapy for all dialysis patients with uremic pruritus includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optimal dialysis since underdialysis is commonly associated with pruritus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"       \"Kt/V and the adequacy of hemodialysis\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H449976\">",
"       'Dialysis modification'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Optimal treatment of hyperparathyroidism, hyperphosphatemia and hypermagnesemia. (See",
"      <a class=\"local\" href=\"#H451070\">",
"       'Parathyroid, calcium, and phosphate'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The regular use of emollients,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      topical analgesics, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/5/17491?source=see_link\">",
"       pramoxine",
"      </a>",
"      lotion. (See",
"      <a class=\"local\" href=\"#H452126\">",
"       'Topical treatments'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H449976\">",
"    <span class=\"h3\">",
"     Dialysis modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing the dose of dialysis may improve pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/23,24,42\">",
"     23,24,42",
"    </a>",
"    ]. The best data are from a 12-month prospective study that included 59 hemodialysis patients without significant disorders of bone metabolism who were stratified according to the degree of pruritus observed over three months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/23\">",
"     23",
"    </a>",
"    ]. In the first phase of the study, during which the dialysis dose was not changed, dialysis adequacy was inversely associated with the severity of pruritus; patients who never had pruritus (n = 16), those who had a reduction in pruritus over three months (n = 16), and those who had prolonged severe pruritus (n = 22) had mean",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    values of 1.31, 1.28, and 1.09, respectively.",
"   </p>",
"   <p>",
"    In a second phase of this study, patients who had severe prolonged pruritus were assigned to receive either increased dialysis (n = 9) or the same dialysis dose (n = 13) for an additional three months with mean follow-up",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    values of 1.19 and 1.07 respectively. The percentage of patients who reported a decrease in pruritus was greater in patients assigned to receive more dialysis compared to those whose dialysis dose did not change (77 versus 8 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Importantly, the highest",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    values reported in this study from 1995 were still lower than the dose that is generally recommended today (which is a single-pool",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    for hemodialysis treatments of 1.4 to 1.6). It is not known whether increasing the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    above the goal values used today confers any additional benefit in decreasing pruritus. We suggest using the generally accepted",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    targets for hemodialysis and peritoneal dialysis patients, because of overall benefit conferred rather than a specific demonstrated effect on pruritus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    For patients who have severe pruritus despite achieving optimal",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    targets and who are highly motivated and able to comply, the dialysis dose may be increased further as a trial. It may be reasonable, for example, to increase the dialysis time for approximately 30 minutes for a one to two week trial. However, no studies have demonstrated a benefit of increasing the dialysis dose above the target values listed above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A modification to the dialysis prescription that has been reported to lessen pruritus is switching to a biocompatible dialysis membrane (such as polymethylmethacrylate [PMMA]) in the rare patient who is being dialyzed with a bioincompatible membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. In the largest study of thirty patients with uremic pruritus, the mean pruritus score decreased four weeks after switching to a PMMA dialyzer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/43\">",
"     43",
"    </a>",
"    ]. Two smaller studies also demonstrated improvement with PMMA membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Virtually all patients in the United States are already dialyzed against a biocompatible membrane however. For patients who are already on a non-PMMA biocompatible membrane, switching to a PMMA membrane may be effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26902?source=see_link\">",
"     \"Clinical consequences of hemodialysis membrane biocompatibility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other changes in dialysate composition have not been shown to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H451070\">",
"    <span class=\"h3\">",
"     Parathyroid, calcium, and phosphate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that the treatment of hyperparathyroidism, hyperphosphatemia and an elevated calcium x phosphate product reduces uremic pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The best data are from a series of 37 hemodialysis patients who underwent parathyroidectomy for bone pain, pruritus alone or bone pain with pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/26\">",
"     26",
"    </a>",
"    ]. The mean PTH level was 1473",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    before surgery and 33",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    postoperatively. Serum calcium and phosphate concentrations were 11.1 and 6.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    preoperatively and 8.4 and 3.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    postoperatively; the calcium x phosphate product decreased with surgery from 72 to 32",
"    <span class=\"nowrap\">",
"     mg2/dL2.",
"    </span>",
"    Pruritus quantitated by a visual analog scale decreased from 5.5 to 1.8; although a statistical correlation between pruritus and preoperative levels of calcium, phosphate, calcium-phosphate product, or PTH could not be demonstrated.",
"   </p>",
"   <p>",
"    However, there are no data that suggest that parathyroidectomy is beneficial in the absence of markedly elevated PTH concentrations such as those present in the study cited above. The optimal PTH and phosphate concentrations that should be maintained in order to prevent or treat uremic pruritus are not known. We suggest targeting the commonly accepted phosphate and PTH concentrations that have been developed for the overall benefit of such patients. Goal phosphate and PTH values for dialysis and non-dialysis chronic kidney disease patients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\", section on 'Goal target levels'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the effect of nonsurgical treatment of hyperparathyroidism, such as vitamin D derivatives and calcimimetics, on uremic pruritus has not been shown, such agents are standard therapy for secondary hyperparathyroidism and should be employed before parathyroidectomy is considered. Parathyroidectomy should be reserved for patients who have elevated PTH, hypercalcemia or hyperphosphatemia that is refractory to medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9273?source=see_link\">",
"     \"Indications for parathyroidectomy in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452126\">",
"    <span class=\"h3\">",
"     Topical treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective topical treatments include emollients and analgesics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/5/17491?source=see_link\">",
"     pramoxine",
"    </a>",
"    hydrochloride.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452115\">",
"    <span class=\"h4\">",
"     Emollients and/or topical analgesic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emollients are the preferred topical treatment of uremic pruritus, especially if xerosis (dry skin) is present on examination. However, only small or uncontrolled trials have been done to establish the efficacy of emollients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one uncontrolled trial of 21 patients, 16 reported significant relief while 9 patients had complete resolution of uremic pruritus with regular emollient use [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Twice daily application of a high water content emollient decreased pruritus among 10 dialysis patients compared to control at two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no good comparative trials between various emollients for uremic pruritus. We suggest using a high water content emollient rather than other agents. The choice of emollient for xerosis in general is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=see_link&amp;anchor=H8354494#H8354494\">",
"     \"Pruritus: Overview of management\", section on 'Xerosis (dry skin)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical analgesic agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/5/17491?source=see_link\">",
"     pramoxine",
"    </a>",
"    , may relieve pruritus. [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/49\">",
"     49",
"    </a>",
"    ]. In one pharmaceutical company-sponsored randomized trial that included 28 hemodialysis patients, twice daily application of pramoxine was associated with a greater reduction in pruritus compared to an emollient (61 versus 12 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/49\">",
"     49",
"    </a>",
"    ]. Pramoxine was shown in this trial to be safe and convenient. Its use might be considered in patients who have persistent symptoms despite appropriate use of emollients.",
"   </p>",
"   <p>",
"    The topical analgesic agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    has been shown in various trials to be effective for localized pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. However, all trials were subsequently criticized for design flaws (mostly lack of adequate blinding and crossover design) that hinder their interpretation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, capsaicin has been used primarily for well circumscribed areas of pruritus; it may not be a practical solution for large areas or generalized pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/9\">",
"     9",
"    </a>",
"    ]. We suggest not using capsaicin for uremic pruritus, unless all other therapies are ineffective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H451660\">",
"    <span class=\"h4\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend NOT using topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    for uremic pruritus. Although early reports suggested a possible benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/14,54\">",
"     14,54",
"    </a>",
"    ], a randomized double-blind study showed no effect of 0.1 percent tacrolimus ointment among 12 hemodialysis patients compared to 8 patients who received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/55\">",
"     55",
"    </a>",
"    ]. In addition, a black box warning has been issued against the prolonged use of topical tacrolimus because of an increased risk of skin malignancies demonstrated in animal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H655794690\">",
"    <span class=\"h2\">",
"     Resistant pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;We define resistant pruritus as continued symptoms despite adequate dialysis, optimization of metabolic parameters, and the use of topical emollients and analgesics for approximately four weeks. Such patients may be treated with an oral antihistamine, and if that is ineffective after a one to two week trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18786081\">",
"    <span class=\"h3\">",
"     Oral antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beneficial effects of antihistamines in pruritus are believed to be mediated via both their sedating properties and ability to stabilize mast cell membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/57\">",
"     57",
"    </a>",
"    ]. We suggest the use of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    (25 mg orally 3-4 times daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (25 mg orally 3-4 times daily) for patients who do not respond to other measures. Some patients, however, may find these agents overly sedating when taken during the day. For such patients, we suggest trying a less sedating agent, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    , during the day, with the continued use of the sedating antihistamines at night. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=see_link&amp;anchor=H8354417#H8354417\">",
"     \"Pruritus: Overview of management\", section on 'Antihistamines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18786088\">",
"    <span class=\"h3\">",
"     Gabapentin",
"    </span>",
"    &nbsp;&mdash;&nbsp;If oral antihistamines provide no relief of symptoms after a one week trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    100 to 400 mg may be given after each hemodialysis session. Gabapentin, a 3-aminobutyric acid analogue anticonvulsant, is used in a variety of neuropathic pain syndromes and has been effective for uremic pruritus at doses of 100 to 300 mg given after dialysis sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized double-blind placebo-controlled crossover study that included 25 hemodialysis patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      (300 mg after each dialysis session) but not placebo, was associated with a significant reduction in pruritus from a visual analog score of 8.4 to 1.2 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 34 hemodialysis patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      400 mg twice weekly was associated with decreased pruritus compared to placebo (visual analog scores of 6.7 and 1.5, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A low dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      (100 mg) after each dialysis decreased pruritus among five patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    is used, the patient should be monitored closely for neurologic side effects such as dizziness and somnolence. The preferred initiating dose is 100 mg after each dialysis session. The dose may be gradually increased to 350 mg daily. Doses greater than 350 mg daily are not recommended in dialysis patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H449784\">",
"    <span class=\"h2\">",
"     Refractory pruritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with uremic pruritus will at least partially respond to emollients, topical analgesics and oral antihistamines or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    . For patients who are refractory to these agents, ultraviolet B phototherapy is a therapeutic option. (See",
"    <a class=\"local\" href=\"#H80902408\">",
"     'Phototherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Pharmacologic manipulation of the opioid system is also a potential therapy for resistant pruritus but there are few studies and conflicting data. We suggest not using specific opioid agonists or antagonists in the absence of further studies, unless all other options have been tried. (See",
"    <a class=\"local\" href=\"#H80902648\">",
"     'Experimental therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Kidney transplantation is definitive therapy for uremic pruritus. As an example, one retrospective study reported that generalized pruritus completely disappeared following successful transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/61\">",
"     61",
"    </a>",
"    ]. For patients who are undecided about whether to undergo a kidney transplant, persistent pruritus may provide incentive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80902408\">",
"    <span class=\"h3\">",
"     Phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultraviolet B (UVB) irradiation is effective in the treatment of uremic pruritus, as noted in small or uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/13,62,63\">",
"     13,62,63",
"    </a>",
"    ]. As an example, in one study, 8 of 10 patients with refractory pruritus reported a significant improvement in symptoms after UVB therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/63\">",
"     63",
"    </a>",
"    ]. The UVB dose was initiated at 200 to 400",
"    <span class=\"nowrap\">",
"     mJ/cm2",
"    </span>",
"    and increased by 100",
"    <span class=\"nowrap\">",
"     mJ/cm2",
"    </span>",
"    at each session to a maximum daily dose of 1500",
"    <span class=\"nowrap\">",
"     mJ/cm2.",
"    </span>",
"    Recurrence of symptoms following cessation of therapy may be a problem; in this study, four patients who responded initially had recurrence of symptoms.",
"   </p>",
"   <p>",
"    The beneficial effects of UVB therapy are thought to be due to a decrease in proinflammatory cytokine levels and induction of mast cell apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/64\">",
"     64",
"    </a>",
"    ]. Specific UVB treatment protocols are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26775?source=see_link\">",
"     \"UVB therapy (broadband and narrowband)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    UVB therapy is associated with an increased risk of carcinogenesis and should not be used in patients who are on immunosuppressive therapy. The carcinogenic potential of UVB irradiation is an issue that should be discussed with all patients for whom such therapy is considered [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/9\">",
"     9",
"    </a>",
"    ]. UVB therapy should not be used in patients with systemic lupus erythematosus because of the known photosensitivity of such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80902648\">",
"    <span class=\"h3\">",
"     Experimental therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many oral therapies have been reported in small series or to be effective for uremic pruritus. These include opioid receptor agonists and antagonists, omega-6 fatty acids, charcoal, 5-hydroxytryptamine receptors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H342232992\">",
"    <span class=\"h4\">",
"     Specific opioid agonists and antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The opioid receptor antagonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    and kappa-opioid receptor agonists, nalfurafine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9543?source=see_link\">",
"     butorphanol",
"    </a>",
"    have been studied for the treatment of uremic pruritus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although a few short term studies suggested that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      was effective for uremic pruritus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/65-68\">",
"       65-68",
"      </a>",
"      ], no benefit was demonstrated in a randomized double-blind, placebo controlled crossover study [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of two multicenter, randomized, double-blind, placebo controlled trials demonstrated decreased pruritus and sleep disturbance among hemodialysis patients who received nalfurafine 5 mcg (intravenously post dialysis) compared with placebo (36 versus 14 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/69\">",
"       69",
"      </a>",
"      ]. Drug-related adverse events were comparable. This agent is currently not available in the United States.",
"     </li>",
"     <li>",
"      A beneficial effect of intranasal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9543?source=see_link\">",
"       butorphanol",
"      </a>",
"      , a kappa-opioid receptor agonist and mu-receptor antagonist was demonstrated in a limited five-patient case series [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16162955\">",
"    <span class=\"h4\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various other therapies have been studied, including omega-6 fatty acid [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/71\">",
"     71",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/72,73\">",
"     72,73",
"    </a>",
"    ], selective inhibitors 5-hydroxytryptamine receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/74\">",
"     74",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/75\">",
"     75",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/76\">",
"     76",
"    </a>",
"    ], nicergoline [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/77\">",
"     77",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/12\">",
"     12",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33024?source=see_link\">",
"     ketotifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/78\">",
"     78",
"    </a>",
"    ], and topical agents gamma linolenic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/79\">",
"     79",
"    </a>",
"    ] and endocannabinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6937/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of these agents in the management of uremic pruritus remains unclear and should only be considered in patients refractory to other therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H656928\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pruritus is common among patients with end stage renal disease. The etiology is not known. Pruritus has been associated with inadequate dialysis and abnormal bone and mineral metabolism as well as xerosis (dry skin caused by sweat gland atrophy). (See",
"      <a class=\"local\" href=\"#H22781493\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30440035\">",
"       'Risk factors and associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment involves a stepwise approach that depends upon the severity of symptoms and the response to initial therapies. Our suggested treatment approach is as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All patients with uremic pruritus should be optimally dialyzed using the generally accepted",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      targets. For patients who have severe pruritus despite achieving optimal",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      targets and who are highly motivated and able to comply, we suggest increasing the dialysis dose as a trial (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"       \"Adequacy of peritoneal dialysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"       \"Kt/V and the adequacy of hemodialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All patients with uremic pruritus should be treated for hyperparathyroidism, hyperphosphatemia, and hypermagnesemia to generally accepted target values.",
"     </li>",
"     <li>",
"      For all patients with uremic pruritus, we recommend treatment with emollients",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      topical analgesics, especially if xerosis or dry skin is present. (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H452115\">",
"       'Emollients and/or topical analgesic agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral antihistamines and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      are occasionally effective for the treatment of pruritus that is resistant to topical therapies. For patients with resistant pruritus despite the use of topical emollients",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      topical analgesics, we suggest an oral antihistamine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H655794690\">",
"       'Resistant pruritus'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      (25 mg orally three to four times daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      (25 mg orally three to four times daily) may be used. Patients who find these agents overly sedating may try a less sedating agent, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      , during the day, with the continued use of the sedating antihistamines at night.",
"      <br/>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      is an anticonvulsant that has been shown to be effective in uremic pruritus. For patients who have resistant pruritus despite oral antihistamines and other therapies, we suggest gabapentin rather than other oral therapies (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The preferred dose is 100 to 350 mg given after each hemodialysis session. If gabapentin is used, the patient should be closely monitored for signs of neurotoxicity and the initial dose should be no more than 100 mg. (See",
"      <a class=\"local\" href=\"#H655794690\">",
"       'Resistant pruritus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapeutic options for refractory uremic pruritus include ultraviolet B phototherapy and kidney transplantation. For patients with refractory pruritus who are not candidates for, or do not wish to undergo kidney transplantation, we suggest ultraviolet B phototherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). UVB therapy is associated with an increased risk of carcinogenesis and should not be used in patients who are on immunosuppressive therapy. The carcinogenic potential should be discussed with all patients for whom such therapy is considered. UVB therapy should not be used in patients with systemic lupus erythematosus because of their known photosensitivity. (See",
"      <a class=\"local\" href=\"#H80902408\">",
"       'Phototherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/1\">",
"      Patel TS, Freedman BI, Yosipovitch G. An update on pruritus associated with CKD. Am J Kidney Dis 2007; 50:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/2\">",
"      Nielsen T, Andersen KE, Kristiansen J. Pruritus and xerosis in patients with chronic renal failure. Dan Med Bull 1980; 27:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/3\">",
"      Bencini PL, Montagnino G, Citterio A, et al. Cutaneous abnormalities in uremic patients. Nephron 1985; 40:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/4\">",
"      Balaskas EV, Chu M, Uldall RP, et al. Pruritus in continuous ambulatory peritoneal dialysis and hemodialysis patients. Perit Dial Int 1993; 13 Suppl 2:S527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/5\">",
"      Wikstr&ouml;m B. Itchy skin--a clinical problem for haemodialysis patients. Nephrol Dial Transplant 2007; 22 Suppl 5:v3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/6\">",
"      Narita I, Alchi B, Omori K, et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 2006; 69:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/7\">",
"      Pisoni RL, Wikstr&ouml;m B, Elder SJ, et al. Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2006; 21:3495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/8\">",
"      Pauli-Magnus C, Mikus G, Alscher DM, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 2000; 11:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/9\">",
"      Kuypers DR. Skin problems in chronic kidney disease. Nat Clin Pract Nephrol 2009; 5:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/10\">",
"      Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus--new perspectives and insights from recent trials. Nephrol Dial Transplant 2002; 17:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/11\">",
"      Kimmel M, Alscher DM, Dunst R, et al. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant 2006; 21:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/12\">",
"      Silva SR, Viana PC, Lugon NV, et al. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron 1994; 67:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/13\">",
"      Gilchrest BA, Rowe JW, Brown RS, et al. Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann Intern Med 1979; 91:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/14\">",
"      Kuypers DR, Claes K, Evenepoel P, et al. A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant 2004; 19:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/15\">",
"      Fallahzadeh MK, Roozbeh J, Geramizadeh B, Namazi MR. Interleukin-2 serum levels are elevated in patients with uremic pruritus: a novel finding with practical implications. Nephrol Dial Transplant 2011; 26:3338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/16\">",
"      Virga G, Visentin I, La Milia V, Bonadonna A. Inflammation and pruritus in haemodialysis patients. Nephrol Dial Transplant 2002; 17:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/17\">",
"      Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003; 361:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/18\">",
"      Umeuchi H, Togashi Y, Honda T, et al. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol 2003; 477:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/19\">",
"      Ikoma A, Steinhoff M, St&auml;nder S, et al. The neurobiology of itch. Nat Rev Neurosci 2006; 7:535.",
"     </a>",
"    </li>",
"    <li>",
"     Kumagai, H, Saruta, T, Matsukawa, S, et al. Prospects for a novel kappa-opioid receptor agonist, TRK-820 in uremic pruritus. In: Itch, Basic Mechanisms and Therapy, Yosipovitch, G, Greaves MW, Fleischer, JA, McGlone, F (Eds), Dekker, New York 2004. p. 286.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/21\">",
"      Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001; 4:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/22\">",
"      Hori T, Oka T, Hosoi M, Aou S. Pain modulatory actions of cytokines and prostaglandin E2 in the brain. Ann N Y Acad Sci 1998; 840:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/23\">",
"      Hiroshige K, Kabashima N, Takasugi M, Kuroiwa A. Optimal dialysis improves uremic pruritus. Am J Kidney Dis 1995; 25:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/24\">",
"      Masi CM, Cohen EP. Dialysis efficacy and itching in renal failure. Nephron 1992; 62:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/25\">",
"      Massry SG, Popovtzer MM, Coburn JW, et al. Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching after subtotal parathyroidectomy. N Engl J Med 1968; 279:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/26\">",
"      Chou FF, Ho JC, Huang SC, Sheen-Chen SM. A study on pruritus after parathyroidectomy for secondary hyperparathyroidism. J Am Coll Surg 2000; 190:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/27\">",
"      Blachley JD, Blankenship DM, Menter A, et al. Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy. Am J Kidney Dis 1985; 5:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/28\">",
"      Duque MI, Thevarajah S, Chan YH, et al. Uremic pruritus is associated with higher kt/V and serum calcium concentration. Clin Nephrol 2006; 66:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/29\">",
"      Rosenthal, SR. Uremic dermatitis. Arch Dermatol Syphil 1931; 23:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/30\">",
"      Cawley, EP, Hoch-Ligeti, C, Bond, GM. The eccrine sweat glands of patients in uremia. Arch Dermatol 1961; 84:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/31\">",
"      Friga V, Linos A, Linos DA. Is aluminum toxicity responsible for uremic pruritus in chronic hemodialysis patients? Nephron 1997; 75:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/32\">",
"      Navarro-Gonz&aacute;lez JF, Mora-Fern&aacute;ndez C, Garc&iacute;a-P&eacute;rez J. Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin Dial 2009; 22:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/33\">",
"      Carmichael AJ, McHugh MM, Martin AM, Farrow M. Serological markers of renal itch in patients receiving long term haemodialysis. Br Med J (Clin Res Ed) 1988; 296:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/34\">",
"      De Marchi S, Cecchin E, Villalta D, et al. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med 1992; 326:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/35\">",
"      Berne B, Vahlquist A, Fischer T, et al. UV treatment of uraemic pruritus reduces the vitamin A content of the skin. Eur J Clin Invest 1984; 14:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/36\">",
"      Charlesworth EN, Beltrani VS. Pruritic dermatoses: overview of etiology and therapy. Am J Med 2002; 113 Suppl 9A:25S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/37\">",
"      Mistik S, Utas S, Ferahbas A, et al. An epidemiology study of patients with uremic pruritus. J Eur Acad Dermatol Venereol 2006; 20:672.",
"     </a>",
"    </li>",
"    <li>",
"     Young, AW, Sweeney, EW, David, DS, et al. Dermatologic evaluation of pruritus in patients on hemodialysis. NY State J Med 1973; 73:2670.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/39\">",
"      Yosipovitch G, Zucker I, Boner G, et al. A questionnaire for the assessment of pruritus: validation in uremic patients. Acta Derm Venereol 2001; 81:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/40\">",
"      Zucker I, Yosipovitch G, David M, et al. Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol 2003; 49:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/41\">",
"      Papa CM. Winter itch, dry skin. J Med Soc N J 1980; 77:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/42\">",
"      Liakopoulos V, Krishnan M, Stefanidis I, et al. Improvement in uremic symptoms after increasing daily dialysate volume in patients on chronic peritoneal dialysis with declining renal function. Int Urol Nephrol 2004; 36:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/43\">",
"      Lin HH, Liu YL, Liu JH, et al. Uremic pruritus, cytokines, and polymethylmethacrylate artificial kidney. Artif Organs 2008; 32:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/44\">",
"      Kato A, Takita T, Furuhashi M, et al. Polymethylmethacrylate efficacy in reduction of renal itching in hemodialysis patients: crossover study and role of tumor necrosis factor-alpha. Artif Organs 2001; 25:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/45\">",
"      Aucella F, Vigilante M, Gesuete A, et al. Uraemic itching: do polymethylmethacrylate dialysis membranes play a role? Nephrol Dial Transplant 2007; 22 Suppl 5:v8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/46\">",
"      Carmichael AJ, Dickinson F, McHugh MI, et al. Magnesium free dialysis for uraemic pruritus. BMJ 1988; 297:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/47\">",
"      Morton CA, Lafferty M, Hau C, et al. Pruritus and skin hydration during dialysis. Nephrol Dial Transplant 1996; 11:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/48\">",
"      Okada K, Matsumoto K. Effect of skin care with an emollient containing a high water content on mild uremic pruritus. Ther Apher Dial 2004; 8:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/49\">",
"      Young TA, Patel TS, Camacho F, et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. J Dermatolog Treat 2009; 20:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/50\">",
"      Tarng DC, Cho YL, Liu HN, Huang TP. Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron 1996; 72:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/51\">",
"      Breneman DL, Cardone JS, Blumsack RF, et al. Topical capsaicin for treatment of hemodialysis-related pruritus. J Am Acad Dermatol 1992; 26:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/52\">",
"      Cho YL, Liu HN, Huang TP, Tarng DC. Uremic pruritus: roles of parathyroid hormone and substance P. J Am Acad Dermatol 1997; 36:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/53\">",
"      Gooding SM, Canter PH, Coelho HF, et al. Systematic review of topical capsaicin in the treatment of pruritus. Int J Dermatol 2010; 49:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/54\">",
"      Pauli-Magnus C, Klumpp S, Alscher DM, et al. Short-term efficacy of tacrolimus ointment in severe uremic pruritus. Perit Dial Int 2000; 20:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/55\">",
"      Duque MI, Yosipovitch G, Fleischer AB Jr, et al. Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. J Am Acad Dermatol 2005; 52:519.",
"     </a>",
"    </li>",
"    <li>",
"     www,fda.gov/medwatch/SAFETY/2005/safety05.htm#Elidel (Accessed on April 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/57\">",
"      Russo GE, Spaziani M, Guidotti C, et al. [Pruritus in chronic uremic patients in periodic hemodialysis. Treatment with terfenadine (an antagonist of histamine H1 receptors)]. Minerva Urol Nefrol 1986; 38:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/58\">",
"      Gunal AI, Ozalp G, Yoldas TK, et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004; 19:3137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/59\">",
"      Naini AE, Harandi AA, Khanbabapour S, et al. Gabapentin: a promising drug for the treatment of uremic pruritus. Saudi J Kidney Dis Transpl 2007; 18:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/60\">",
"      Manenti L, Vaglio A, Costantino E, et al. Gabapentin in the treatment of uremic itch: an index case and a pilot evaluation. J Nephrol 2005; 18:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/61\">",
"      Altmeyer P, Kachel HG, Sch&auml;fer G, Fassbinder W. [Normalization of uremic skin changes following kidney transplantation]. Hautarzt 1986; 37:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/62\">",
"      Szepietowski JC, Schwartz RA. Uremic pruritus. Int J Dermatol 1998; 37:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/63\">",
"      Ada S, Se&ccedil;kin D, Budako��lu I, Ozdemir FN. Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study. J Am Acad Dermatol 2005; 53:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/64\">",
"      Szepietowski JC, Morita A, Tsuji T. Ultraviolet B induces mast cell apoptosis: a hypothetical mechanism of ultraviolet B treatment for uraemic pruritus. Med Hypotheses 2002; 58:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/65\">",
"      Bernstein JE, Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 1979; 115:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/66\">",
"      Andersen LW, Friedberg M, Lokkegaard N. Naloxone in the treatment of uremic pruritus: a case history. Clin Nephrol 1984; 21:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/67\">",
"      Peer G, Kivity S, Agami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996; 348:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/68\">",
"      Legroux-Crespel E, Cl&egrave;des J, Misery L. A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology 2004; 208:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/69\">",
"      Wikstr&ouml;m B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005; 16:3742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/70\">",
"      Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006; 54:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/71\">",
"      Yoshimoto-Furuie K, Yoshimoto K, Tanaka T, et al. Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients. Nephron 1999; 81:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/72\">",
"      Pederson JA, Matter BJ, Czerwinski AW, Llach F. Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal. Ann Intern Med 1980; 93:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/73\">",
"      Giovannetti S, Barsotti G, Cupisti A, et al. Oral activated charcoal in patients with uremic pruritus. Nephron 1995; 70:193.",
"     </a>",
"    </li>",
"    <li>",
"     Layeg, P, Mojahedi, MJ, Malekshah, PE et al. Effect of oral granisetron in uremic pruritis. Indian Jounal of Dermatology, Venereology and Leprology 2007; 73:231.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/75\">",
"      Rosner MH. Cromolyn sodium: a potential therapy for uremic pruritus? Hemodial Int 2006; 10:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/76\">",
"      Silverberg DS, Iaina A, Reisin E, et al. Cholestyramine in uraemic pruritus. Br Med J 1977; 1:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/77\">",
"      Bousquet J, Rivory JP, Maheut M, et al. Double-blind, placebo-controlled study of nicergoline in the treatment of pruritus in patients receiving maintenance hemodialysis. J Allergy Clin Immunol 1989; 83:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/78\">",
"      Francos GC, Kauh YC, Gittlen SD, et al. Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus. Int J Dermatol 1991; 30:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/79\">",
"      Chen YC, Chiu WT, Wu MS. Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus. Am J Kidney Dis 2006; 48:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6937/abstract/80\">",
"      Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat 2005; 13:97.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1985 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.44.181.18-12223B0A2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_49_6937=[""].join("\n");
var outline_f6_49_6937=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H656928\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22781493\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98332764\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14965810\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1729208\">",
"      Immunohypothesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1729277\">",
"      Opioid hypothesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22425983\">",
"      Other contributing factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30440035\">",
"      RISK FACTORS AND ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22781508\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22781515\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30440440\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22781529\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H655794683\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H449976\">",
"      - Dialysis modification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H451070\">",
"      - Parathyroid, calcium, and phosphate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H452126\">",
"      - Topical treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H452115\">",
"      Emollients and/or topical analgesic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H451660\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H655794690\">",
"      Resistant pruritus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18786081\">",
"      - Oral antihistamines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18786088\">",
"      - Gabapentin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H449784\">",
"      Refractory pruritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H80902408\">",
"      - Phototherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H80902648\">",
"      - Experimental therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H342232992\">",
"      Specific opioid agonists and antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16162955\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H656928\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1985\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1985|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/61/14296\" title=\"picture 1\">",
"      Skin lesions pts uremic pruritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=related_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26902?source=related_link\">",
"      Clinical consequences of hemodialysis membrane biocompatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35400?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=related_link\">",
"      Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9273?source=related_link\">",
"      Indications for parathyroidectomy in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23863?source=related_link\">",
"      Pruritus associated with cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10090?source=related_link\">",
"      Pruritus: Etiology and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=related_link\">",
"      Pruritus: Overview of management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26775?source=related_link\">",
"      UVB therapy (broadband and narrowband)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_49_6938="Invasive cervical adenocarcinoma";
var content_f6_49_6938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Invasive cervical adenocarcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/49/6938/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6938/contributors\">",
"     Marcela G del Carmen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6938/contributors\">",
"     John O Schorge, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/49/6938/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6938/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/49/6938/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6938/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/49/6938/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/49/6938/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H553367437\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cancer encompasses several histologic types, of which squamous cell carcinoma (SCC) is the most common (70 percent) (",
"    <a class=\"graphic graphic_table graphicRef65824 \" href=\"UTD.htm?2/38/2668\">",
"     table 1",
"    </a>",
"    ). The incidence of invasive cervical adenocarcinoma and its variants has increased dramatically over the past few decades; this cell type now accounts for about 25 percent of all invasive cervical cancers diagnosed in the United States (US) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Neuroendocrine (predominantly small cell poorly differentiated) carcinomas and other rare cell types together comprise 3 to 5 percent of all cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5498?source=see_link\">",
"     \"Small cell neuroendocrine carcinoma of the cervix\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of our knowledge on the treatment of cervical cancer comes from studies in which the majority of the patients had SCC; adenocarcinoma has comprised, on average, 10 percent of the cases. Very few of these studies report separate outcomes for adenocarcinoma, and no prospective study has focused on the treatment of adenocarcinoma as the sole histology. As a result, our understanding of the natural history and optimal management of adenocarcinoma of the cervix is limited.",
"   </p>",
"   <p>",
"    There are many similarities between adenocarcinoma and SCC of the cervix, and they are treated the same at most institutions. However, there are also several differences in epidemiology, prognostic factors, patterns of failure after primary treatment, and possibly of response to specific treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/3\">",
"     3",
"    </a>",
"    ]. Despite these differences, specific treatment strategies tailored to adenocarcinoma have not yet emerged.",
"   </p>",
"   <p>",
"    This topic will focus on unique issues pertaining to invasive cervical adenocarcinoma. Clinical features, staging, and management issues that are common to SCC and adenocarcinoma, as well as adenocarcinoma in situ, are discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link\">",
"     \"Management of early stage cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link\">",
"     \"Management of locally advanced cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37736?source=see_link\">",
"     \"Cervical adenocarcinoma in situ\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175461\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are both similarities and differences in the epidemiology of adenocarcinoma of the cervix compared to SCC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of invasive cervical adenocarcinoma and its variants has increased dramatically over the past few decades, particularly in younger women [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Several causative factors have been proposed to explain this trend, including increased prevalence of specific HPV-16 and 18 variants that are associated more with adenocarcinoma than with SCC as well as exposure to endogenous (eg, obesity) as well as exogenous (eg, hormonal contraception, postmenopausal estrogen therapy) estrogens.",
"     </li>",
"     <li>",
"      The mean age at diagnosis of invasive cervical adenocarcinoma is the early 50s [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/6\">",
"       6",
"      </a>",
"      ]. This is nearly the same as the mean age at diagnosis of SCC, which is 47 years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link&amp;anchor=H7674594#H7674594\">",
"       \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\", section on 'Incidence and mortality'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cervical adenocarcinoma shares some of the same risk factors with SCC, the most important of which is prolonged infection with high-risk subtypes of human papillomavirus (HPV), particularly subtypes 16 and 18 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/7-9\">",
"       7-9",
"      </a>",
"      ]. However, adenocarcinoma and SCC have slightly different associations with HPV genotypes [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. The available data suggests that HPV-18 accounts for approximately 50 percent of adenocarcinomas compared to 15 percent of SCCs, and that the proportion of adenocarcinomas associated with HPV 16 and 18 infections is higher in adenocarcinomas relative to that of SCC, which is associated with a greater diversity of HPV types [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link&amp;anchor=H3#H3\">",
"       \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\", section on 'Epidemiology and risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast to its squamous counterpart, cigarette smoking does not appear to be a risk factor for adenocarcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A pooled analysis of data from eight case-control studies suggests that parity has a weaker association, while obesity had a stronger association with adenocarcinoma as compared to SCC [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Exposure to exogenous estrogens (eg, hormonal contraception, postmenopausal estrogen therapy) is a risk factor for adenocarcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/12-15\">",
"       12-15",
"      </a>",
"      ]. However, a systematic review concluded that use of oral contraceptives was a risk factor for both adenocarcinoma and SCC [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H553367444\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical adenocarcinomas of the usual endocervical type account for at least 80 percent of cervical adenocarcinomas. Although classified as mucinous adenocarcinomas, most are only focally mucinous [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/17\">",
"     17",
"    </a>",
"    ]. They are characterized by an irregular haphazard arrangement of glands lined by cells resembling those that line normal endocervical glands.",
"   </p>",
"   <p>",
"    Pure or almost pure mucinous adenocarcinomas do occur, including an intestinal type, signet ring cell variant, and an important subtype, minimal deviation adenocarcinoma (adenoma malignum), which has a bland cytologic appearance and may be mistaken for a benign lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/17\">",
"     17",
"    </a>",
"    ]. The precursor lesion of most invasive cervical adenocarcinomas is believed to be adenocarcinoma in situ (AIS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37736?source=see_link\">",
"     \"Cervical adenocarcinoma in situ\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adenosquamous carcinoma is a tumor composed of admixed malignant glandular and squamous elements. It does not appear to originate from AIS and demonstrates more aggressive features than other cervical adenocarcinomas, such as higher tumor grade and lymphovascular invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endometrioid-type adenocarcinomas with the characteristic histology of tubular glands are infrequently diagnosed, but they have a better prognosis than adenocarcinomas of the usual endocervical type [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These tumors display histologic features that are identical to endometrial carcinomas, and the possibility of a primary endometrial adenocarcinoma with endocervical extension or drop metastasis must be excluded before the diagnosis of a primary endocervical endometrioid adenocarcinoma is established.",
"   </p>",
"   <p>",
"    Despite the better prognosis, management for endometrioid histology is generally the same as for other cervical adenocarcinomas. (See",
"    <a class=\"local\" href=\"#H553367451\">",
"     'Specific management issues'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175741\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of cervical adenocarcinoma are the same as for SCC. Many women are asymptomatic and, where cervical cancer screening is routinely performed, cervical adenocarcinoma is most commonly detected through cervical cytology. When symptoms occur, women are most likely to present with postcoital bleeding. In some women, a cervical mass is discovered upon pelvic examination that is performed for other indications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link&amp;anchor=H6#H6\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link&amp;anchor=H4#H4\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'The Papanicolaou smear'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175763\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with SCC, cervical adenocarcinoma is diagnosed with a cervical biopsy. The depth of invasion, which correlates with the incidence of metastatic disease, is measured from the luminal surface of the tumor or overlying benign epithelium to the deepest invasive tumor nest [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/20\">",
"     20",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The vast majority of adenocarcinomas have an obvious invasive component. The exception to this is microinvasive disease. Microinvasive cervical adenocarcinoma (also termed early invasive adenocarcinoma,",
"    <span class=\"nowrap\">",
"     FIGO/AJCC",
"    </span>",
"    stage IA1 or 1A2 disease, (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 2",
"    </a>",
"    )) is most commonly detected postoperatively on a conization performed for presumed adenocarcinoma in situ (AIS). (See",
"    <a class=\"local\" href=\"#H453094955\">",
"     'Staging system'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Conization is required to define the microinvasive lesion and a negative margin is required to confirm the absence of additional disease. This is particularly important for cervical adenocarcinoma, since, in contrast to cervical SCC, noncontiguous lesions (&ldquo;skip lesions&rdquo;) are often found. In general, we do not recommend additional biopsies in the setting of a negative conization margin.",
"   </p>",
"   <p>",
"    If the conization margin is positive for invasive tumor, a second conization is mandatory. If there is no residual disease on the second procedure, then a diagnosis of microinvasive (stage IA1 or IA2) disease can safely be made. If the second conization demonstrates additional invasive disease, then it should be classified as invasive disease and staged accordingly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453094955\">",
"    <span class=\"h2\">",
"     Staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The staging schema for cervical adenocarcinoma and its variants is the same as for SCC. The joint International Federation of Gynecology and Obstetrics (FIGO) and American Joint Committee on Cancer (AJCC) staging system is listed in the table (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 2",
"    </a>",
"    ). Although not explicitly stated in the staging table, involvement of the upper two-thirds of the vagina is also considered stage IIA disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453094962\">",
"    <span class=\"h2\">",
"     Staging workup",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with SCCs, FIGO guidelines only allow the use of readily available techniques, such as physical examination, proctoscopy, and intravenous pyelogram, for assigning stage. Optional testing modalities (eg, CT, positron emission tomography [PET]) are widely performed, where available, and the results of these tests are used for planning treatment, but not for staging.",
"   </p>",
"   <p>",
"    The urinary tract should be imaged in all patients with more than microscopic disease; most clinicians use CT urography, MRI, or fused",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    rather than IVP. This provides information about disease in the upper abdomen and retroperitoneum in addition to evaluating for hydronephrosis. Suspicion of lymphadenopathy in the region of the pelvic or paraaortic lymph nodes may alter the treatment plan. We usually recommend both a",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    and an MRI scan in women with microscopically invasive or more advanced stage cervical adenocarcinoma to help guide treatment. (See",
"    <a class=\"local\" href=\"#H381109989\">",
"     'Role and extent of lymphadenectomy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H553367466\">",
"     'Locoregionally advanced (IIB-IVA) disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link&amp;anchor=H5#H5\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\", section on 'Staging procedure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link&amp;anchor=H6#H6\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\", section on 'Further evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1362292\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS AND DIFFERENCES IN OUTCOME COMPARED TO SCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major prognostic factors for cervical adenocarcinoma are the same as for SCC, including stage, nodal status, tumor volume, depth of cervical stromal invasion, lymphovascular space invasion, and grade [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H22#H22\">",
"     \"Management of early stage cervical cancer\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is controversy as to whether histologic type is an independent prognostic factor in cervical cancer. When adjusted for stage, some series support the prognostic equivalence of cervical adenocarcinoma versus SCC, but most have shown that adenocarcinoma carries a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/24-31\">",
"     24-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest studies included 24,562 patients with cervical cancer from the Surveillance, Epidemiology and End Results database, of whom 77, 17, and 6 percent had squamous cell, adenocarcinoma, and adenosquamous carcinoma, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/31\">",
"     31",
"    </a>",
"    ]. The main findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased risk of death for women with adenocarcinoma compared to squamous cell carcinoma (odds ratio [OR] 1.39, 95% CI 1.23-1.56) who presented with early-stage cervical cancer (stage IB1-IIA) (",
"      <a class=\"graphic graphic_table graphicRef76037 \" href=\"UTD.htm?26/53/27485\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      An increased risk of death for women with adenocarcinoma who presented with higher-stage disease (stage IIB-IVA) (OR 1.21, 95% CI 1.10-1.32).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The worse outcomes reported in many series has been attributed to several factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher rate of distant metastases with adenocarcinomas (particularly those &gt;4 cm) compared to SCC [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/4,30,32,33\">",
"       4,30,32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Higher rates of HPV-18 infection [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      A higher incidence of nodal metastases with (32 versus 15 percent with SCC in one series [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/36\">",
"       36",
"      </a>",
"      ]) and a significantly worse overall survival among those who have lymphatic metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/29,36,37\">",
"       29,36,37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96574101\">",
"    <span class=\"h2\">",
"     Differences in patterns of dissemination and recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patterns of dissemination and disease recurrence differ with adenocarcinoma and SCC histology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ovarian metastases are more common with adenocarcinoma than with SCC (5 versus 0.8 percent in one series [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/38\">",
"       38",
"      </a>",
"      ]). As a result of this, we usually recommend removal of the ovaries at the time of hysterectomy. &nbsp;",
"     </li>",
"     <li>",
"      A number of studies demonstrate higher rates of distant metastases (ascites, abdominal carcinomatosis, and paraortic spread) with adenocarcinomas [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/22,25\">",
"       22,25",
"      </a>",
"      ]. As an example, in a comparative series of patients with stage IB cervical adenocarcinoma (n = 219) or SCC (n = 1503) treated with radiation therapy, rates of distant relapse were significantly higher with adenocarcinoma (",
"      <a class=\"graphic graphic_table graphicRef69374 \" href=\"UTD.htm?16/16/16651\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96574449\">",
"    <span class=\"h2\">",
"     Differences in treatment response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the data that guide the treatment of cervical cancer comes from randomized trials in which the majority of the patients had SCC; adenocarcinoma has comprised, on average, 10 percent of the cases. None of these studies report separate outcomes for adenocarcinoma, and no prospective study has focused on the treatment of adenocarcinoma as the sole histology. As a result, treatment for adenocarcinoma follows the principles established for cervical SCC at most institutions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link\">",
"     \"Management of locally advanced cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link\">",
"     \"Management of early stage cervical cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, data from some of these randomized trials that report subgroup analysis according to cell type suggest that treatments might have different effects on recurrence rates and survival:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Gynecologic Oncology Group (GOG) trial 92 randomly assigned 277 patients (59 with non-SCC histology) with surgically treated stage IB cervical cancer, negative nodes, and at least two adverse prognostic factors to adjuvant external beam RT (EBRT) or observation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/39\">",
"       39",
"      </a>",
"      ]. In subset analysis, the addition of adjuvant RT appeared to be more effective in reducing the risk of recurrence for non-SCC tumors (recurrence rate with observation versus EBRT was 44 versus 9 percent; the corresponding values for SCC were 28 versus 20 percent).",
"     </li>",
"     <li>",
"      A second US Intergroup trial compared chemoradiotherapy versus RT alone in 243 patients (50 adenocarcinomas) with resected stage IA2, IB, or IIA cervical cancer with high-risk features [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/40\">",
"       40",
"      </a>",
"      ]. In subgroup analysis, patients with adenocarcinoma had a worse prognosis than SCC when treated with RT alone; this difference disappeared in patients who received chemotherapy in addition to RT.",
"     </li>",
"     <li>",
"      Another trial included patients with stage IB or IIA cervical cancer who were randomly assigned to surgery (n = 172) or radical RT (n = 171); 46 patients had adenocarcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/41\">",
"       41",
"      </a>",
"      ]. In the entire cohort, five-year disease-free and overall survival were not different between the surgery and RT arms; however, among those with adenocarcinoma, there appeared to be a significant advantage for surgery compared to RT alone (five-year overall survival 70 versus 59 percent, disease-free survival 66 versus 47 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data raise the possibility that patients with adenocarcinoma respond differently to specific components of treatment than do those with SCC. It is possible that RT as part of management is more effective in this histology for local control in stage IB tumors. However, even with adequate pelvic control in those treated with RT, distant relapse rates are higher, raising the question of whether distant relapse could be prevented (and outcomes improved) through the routine use of adjuvant systemic treatment. However, these results are from unplanned subset analyses of small groups of patients, and they should be considered hypothesis generating, at best. Exploration of optimal treatment for adenocarcinoma of the cervix in prospective randomized trials is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H553367451\">",
"    <span class=\"h1\">",
"     SPECIFIC MANAGEMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;General principles of management, particularly where they vary from those for SCC, are presented here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H553368259\">",
"    <span class=\"h2\">",
"     Microinvasive (IA1-IA2) disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of microinvasive cervical adenocarcinoma depends upon patient age and desire to maintain fertility. The prognosis of microinvasive adenocarcinoma is generally excellent, and conservative, nonradical surgery is appropriate for some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. As an example, an overall relapse rate of 3 percent was found in a national US cancer database (Surveillance, Epidemiology and End-Results [SEER]) study of 1170 patients with surgically treated microinvasive cervical adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Stage IA1",
"      </strong>",
"      &mdash; For stage IA1 disease with widely negative margins on cold knife conization, simple hysterectomy is a reasonable option for women who are postmenopausal or do not wish to preserve fertility. Pelvic lymphadenectomy is not necessary. (See",
"      <a class=\"local\" href=\"#H553367480\">",
"       'Fertility preservation'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Stage IA2",
"      </strong>",
"      &mdash; We tend to perform a modified radical hysterectomy for stage IA2 lesions; the added surgical morbidity of this approach compared with simple hysterectomy is minimal when performed by experienced gynecologic oncologists. In a modified radical hysterectomy, the uterine artery is ligated where it crosses over the ureter, the uterosacral and cardinal ligaments are divided midway towards their attachment to the sacrum and the pelvic side wall, respectively, so that the parametrium medial to the ureter is removed, as well as the upper one third of the vagina is resected (",
"      <a class=\"graphic graphic_table graphicRef57850 \" href=\"UTD.htm?13/29/13788\">",
"       table 5",
"      </a>",
"      ). We also include a pelvic lymph node dissection for stage IA2 disease. (See",
"      <a class=\"local\" href=\"#H381109989\">",
"       'Role and extent of lymphadenectomy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link\">",
"       \"Management of early stage cervical cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H553367459\">",
"    <span class=\"h2\">",
"     Invasive early stage (IB1-IIA) disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage IB and IIA cervical cancer can be cured by either surgery (usually radical hysterectomy, bilateral salpingo-oophorectomy and pelvic lymph node dissection) or radiotherapy (RT), which is typically administered with concurrent chemotherapy (chemoradiotherapy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H546744743#H546744743\">",
"     \"Management of early stage cervical cancer\", section on 'Primary therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the management of early stage invasive cervical adenocarcinoma and its variants is similar, stage for stage, to that of SCC, with some minor modifications [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/20,45\">",
"     20,45",
"    </a>",
"    ]. As an example, the risk of ovarian metastases is higher in women with cervical adenocarcinoma than among those with SCC (2 versus 0.5 percent in one GOG study of women with stage IB cervical cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/46\">",
"     46",
"    </a>",
"    ], and women with cervical adenocarcinoma who are appropriate for surgical treatment should undergo oophorectomy at the time of hysterectomy.",
"   </p>",
"   <p>",
"    The general principles that guide therapy are to offer patients single modality treatment if at all possible and to avoid radical surgery followed by chemoradiotherapy. Surgery is generally preferred over initial chemoradiotherapy if the patient is an appropriate candidate for surgery, given the lower rate of long-term treatment-related adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/45,47\">",
"     45,47",
"    </a>",
"    ]. However, if risk factors are identified pretreatment (eg, evidence of lymph node involvement on pretreatment imaging, tumor size &gt;4 cm, deep stromal invasion to the middle or deep one-third, or lymphovascular space invasion as seen in the initial biopsy) that indicate the need for adjuvant therapy after surgery, then we prefer upfront chemoradiotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H618915858#H618915858\">",
"     \"Management of early stage cervical cancer\", section on 'Treatment of high-risk disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The preference for surgery is based upon data from a prospective trial in which 343 women with stage IB and IIA cervical cancer (14 percent adenocarcinoma) adenocarcinoma were randomly assigned to primary surgery or radiotherapy (but without concurrent chemotherapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/41,48\">",
"     41,48",
"    </a>",
"    ]. At a median follow-up of 87 months, the five-year overall and disease-free survival rates were the same for both treatment groups (83 and 74 percent, respectively). However, multivariate analysis demonstrated a survival advantage for patients with adenocarcinoma who underwent primary surgery. It remains to be determined whether this result was due to an increased effectiveness of surgery or the absence of a benefit from radiotherapy (possibly due to the lack of concurrent chemotherapy) in women with adenocarcinoma.",
"   </p>",
"   <p>",
"    As noted above, some data raise the possibility that adenocarcinomas have a poorer outcome with RT alone than do SCCs, but that relative radioresistance might be overcome through the use of concurrent chemotherapy. As a result, when RT is administered for adenocarcinoma, we usually give concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy. (See",
"    <a class=\"local\" href=\"#H96574449\">",
"     'Differences in treatment response'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link\">",
"     \"Management of early stage cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H618915858#H618915858\">",
"     \"Management of early stage cervical cancer\", section on 'Treatment of high-risk disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10754335\">",
"    <span class=\"h3\">",
"     Posttreatment extrafascial hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrafascial hysterectomy is not routinely performed following chemoradiotherapy because chemoradiotherapy alone yields low local recurrence rates. The benefit of postradiotherapy surgery was addressed in a GOG trial in which 256 women with cervical cancer &gt;4 cm were randomly assigned to RT alone or RT followed by surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/49\">",
"     49",
"    </a>",
"    ]. While the surgery group had lower rates of local relapse at five years (14 versus 27 percent), survival was not improved. &nbsp;",
"   </p>",
"   <p>",
"    A simple extrafascial hysterectomy could be considered for patients at high risk for a poor outcome with chemoradiotherapy alone, although there is no consensus as to which patients fit this category. We consider this approach for patients with early stage cervical cancer and no evidence of nodal involvement who have an initially large cervical lesion (&gt;7 cm), lower uterine segment involvement, or a high residual tumor volume after chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/50\">",
"     50",
"    </a>",
"    ]. Although such an approach has the potential to enhance local control, patients will be exposed to the combined morbidity of radical surgery and radiotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link&amp;anchor=H10523258#H10523258\">",
"     \"Management of locally advanced cervical cancer\", section on 'Role of hysterectomy after chemoradiation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H381109989\">",
"    <span class=\"h3\">",
"     Role and extent of lymphadenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodal metastases are the most important prognostic variable for cervical cancer. Lymph node metastases portend a poor outcome, particularly among those with adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/27\">",
"     27",
"    </a>",
"    ]. Detecting their presence is crucial to guide treatment planning.",
"   </p>",
"   <p>",
"    Pelvic lymphadenectomy is a mandatory component of initial surgery for early stage, operable cervical adenocarcinoma (stage IA2, IB1 and IIA disease), as it is with SCC. However, unless there is gross evidence of nodal or adnexal disease at the time of visual inspection during surgery, extension of the node dissection to include the paraaortic lymph nodes is not mandatory [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/51\">",
"     51",
"    </a>",
"    ]. We consider that patients who have suspicious lymph nodes on pretreatment imaging are more appropriate for initial chemoradiotherapy than surgery. The role of therapeutic debulking lymphadenectomy in such patients is controversial and discussed below. (See",
"    <a class=\"local\" href=\"#H453095633\">",
"     'Role of therapeutic lymphadenectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453095097\">",
"    <span class=\"h3\">",
"     Indications for adjuvant therapy after hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with cervical SCC, women with",
"    <strong>",
"     one or more",
"    </strong>",
"    of the following findings are considered to be at",
"    <strong>",
"     high risk",
"    </strong>",
"    for recurrent disease, and should receive adjuvant chemoradiotherapy following hysterectomy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Positive or close resection margins",
"     </li>",
"     <li>",
"      Positive lymph nodes",
"     </li>",
"     <li>",
"      Microscopic parametrial involvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H618915858#H618915858\">",
"     \"Management of early stage cervical cancer\", section on 'Treatment of high-risk disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adjuvant therapy is also recommended for women at intermediate risk of recurrence (large tumor size, deep cervical stromal invasion to the middle or deep one-third, or lymphovascular space invasion), but at least for SCC, there is less consensus on the optimal form of adjuvant therapy (RT versus chemoradiotherapy). In view of the above data suggesting that adenocarcinomas have a poorer outcome with RT alone than do SCCs, but that relative radioresistance might be overcome through the use of concurrent chemotherapy, we usually administer concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy. (See",
"    <a class=\"local\" href=\"#H96574449\">",
"     'Differences in treatment response'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H618915851#H618915851\">",
"     \"Management of early stage cervical cancer\", section on 'Treatment of intermediate-risk disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H553367466\">",
"    <span class=\"h2\">",
"     Locoregionally advanced (IIB-IVA) disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with locoregionally advanced cervical SCC, primary radiotherapy has been the treatment of choice at most institutions, although practice varies. Guidelines from the National Comprehensive Cancer Network (NCCN) suggest either radical hysterectomy or initial chemoradiotherapy in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in our view, these patients should be approached initially with chemoradiotherapy. One of the main arguments against a primary surgical approach in this setting is the high potential for multimodality therapy, given that the majority of women will have high-risk or intermediate-risk disease for which postoperative chemoradiotherapy is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of locally advanced cervical cancer\", section on 'Definition of locally advanced stage cervical cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link\">",
"     \"Management of locally advanced cervical cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple randomized phase III trials, which enrolled predominantly SCC, as well as a meta-analysis have confirmed the survival benefit of adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based concurrent chemotherapy to RT for primary treatment of locally advanced cervical cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of locally advanced cervical cancer\", section on 'Primary chemoradiation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is reasonable to apply these results to adenocarcinoma and its variants for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These trials included women with adenocarcinoma histology.",
"     </li>",
"     <li>",
"      There is evidence that early-stage cervical adenocarcinomas are sensitive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemoradiation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adenocarcinoma-specific phase III trials cannot feasibly be conducted due to the low incidence of glandular disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the dismal prognosis of all histologic types of advanced disease, especially stage III and IV, emphasizes the need for novel approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/50,53\">",
"     50,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453095633\">",
"    <span class=\"h3\">",
"     Role of therapeutic lymphadenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of therapeutic lymphadenectomy in patients undergoing primary chemoradiotherapy for locoregionally advanced cervical cancer is controversial. Surgical staging is the most accurate method of determining lymph node involvement, which is one of the most important prognostic factors. In addition, there is a potential therapeutic survival benefit of resecting lymph nodes, particularly bulky nodes, prior to chemoradiotherapy, but this has not been proven.",
"   </p>",
"   <p>",
"    For both cervical SCC and adenocarcinoma, some clinicians use the results of radiographic staging studies to select women for a therapeutic lymphadenectomy. Preirradiation staging lymphadenectomy (which can be accomplished laparoscopically or robotically) may be offered to medically fit patients if they have evidence of bulky nodes on CT scan, or if a pretreatment PET or",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    shows uptake of FDG in the region of the infrarenal paraaortic or pelvic lymph nodes. If both are negative, routine staging lymphadenectomy is not performed. Guidelines from the National Comprehensive Cancer Network (NCCN) suggest consideration of an extraperitoneal lymph node in this situation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link&amp;anchor=H20013012#H20013012\">",
"     \"Management of locally advanced cervical cancer\", section on 'Pretreatment evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link&amp;anchor=H30045461#H30045461\">",
"     \"Management of locally advanced cervical cancer\", section on 'Treatment of para-aortic nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the controversy as to whether debulking of nodes is associated with a real survival advantage, we generally do not perform a therapeutic lymphadenectomy in patients undergoing primary chemoradiotherapy who have bulky adenopathy identified on pretreatment imaging. However, this is a controversial area, and some clinicians would recommend removal of suspicious nodes in good surgical candidates. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453095363\">",
"    <span class=\"h3\">",
"     Neoadjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCC of the cervix is a chemosensitive neoplasm particularly when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based regimens are used, and neoadjuvant chemotherapy is an accepted approach for patients with locally advanced disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link&amp;anchor=H10523617#H10523617\">",
"     \"Management of locally advanced cervical cancer\", section on 'Neoadjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adenocarcinomas are similarly chemotherapy sensitive, at least in the setting of advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/24,54\">",
"     24,54",
"    </a>",
"    ]. The use of neoadjuvant chemotherapy may be beneficial in selected women. This strategy was investigated in a report in which 16 women with cervical adenocarcinoma or adenosquamous carcinoma received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    (median three courses) prior to radical hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/55\">",
"     55",
"    </a>",
"    ]. There were three complete and five partial responders (objective response rate 50 percent). Of the 12 patients who subsequently underwent surgery, histologic changes correlated well with the clinical response. Similar data have been reported by others [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/54,56,57\">",
"     54,56,57",
"    </a>",
"    ]. However, long-term results are not available, and whether this strategy provides superior outcomes over chemoradiotherapy is unknown.",
"   </p>",
"   <p>",
"    In our view, this approach should be considered experimental for adenocarcinomas and not pursued outside of the context of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H553367473\">",
"    <span class=\"h2\">",
"     Stage IVB, persistent and recurrent disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453095659\">",
"    <span class=\"h3\">",
"     Surgery and/or RT for localized recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following radical hysterectomy or definitive chemoradiotherapy for early stage cervical squamous cell cancer, the predominant site of disease recurrence is local (vaginal apex) or regional (pelvic sidewall). The same holds true for adenocarcinoma. Exenterative surgery is an option only for those few patients with centrally relapsed disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link&amp;anchor=H8642804#H8642804\">",
"     \"Management of recurrent or metastatic cervical cancer\", section on 'Candidates for surgical resection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453095652\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with more extensive primary or locoregionally relapsed disease or distant metastatic disease are usually treated with chemotherapy. Small prospective studies have evaluated the response of adenocarcinoma to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/24,54,58-60\">",
"     24,54,58-60",
"    </a>",
"    ], but in general, they are managed similarly to SCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link&amp;anchor=H104509204#H104509204\">",
"     \"Management of recurrent or metastatic cervical cancer\", section on 'Metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the Gynecologic Oncology Group (GOG) no longer conducts clinical trials in non-SCC cervical carcinoma because it was deemed not to be feasible and the available data suggesting similar outcomes when nonsquamous and squamous cervical cancers are treated with platinum-based combination chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We prefer that eligible women enroll on clinical trials testing new strategies. However, if a clinical trial is not available or feasible, we treat these patients similar to those with SCC. Our preferred chemotherapy regimen consists of a platinum-based combination (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ). On the basis of the results of GOG 240, we also incorporate the angiogenesis inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in the first-line treatment setting. The results of GOG 240 are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link&amp;anchor=H2177909474#H2177909474\">",
"     \"Management of recurrent or metastatic cervical cancer\", section on 'First-line treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link&amp;anchor=H104509204#H104509204\">",
"     \"Management of recurrent or metastatic cervical cancer\", section on 'Metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women with a poor performance status and those who progress following first-line therapy, acceptable options include single agent chemotherapy, best supportive care,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    palliative RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link&amp;anchor=H85099849#H85099849\">",
"     \"Management of recurrent or metastatic cervical cancer\", section on 'Second-line therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550393653\">",
"    <span class=\"h3\">",
"     Surgery for metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection may be useful in carefully selected patients with cervical adenocarcinomas who have isolated pulmonary metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H553367480\">",
"    <span class=\"h2\">",
"     Fertility preservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management dilemma in women with cervical adenocarcinoma who wish to preserve fertility is complicated by the inherent risks of residual disease and the relatively poor predictive value of conization margins. This is of somewhat greater concern than with squamous disease, since adenocarcinoma tends to be multifocal. Fertility preservation in women with cervical cancer is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9898?source=see_link\">",
"     \"Fertility sparing surgery for invasive cervical cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H553367487\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal surveillance strategy has not been established and clinical practice is variable. Posttreatment surveillance for invasive cervical cancer is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/42/17064?source=see_link\">",
"     \"Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28163?source=see_link\">",
"       \"Patient information: Cervical cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=see_link\">",
"       \"Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176666\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical adenocarcinoma comprises 25 percent of invasive cervical cancers; squamous cell cancers (SCCs) account for 70 percent. (See",
"      <a class=\"local\" href=\"#H553367437\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some risk factors for cervical adenocarcinoma are shared with squamous disease, particularly infection with high risk subtypes of human papillomavirus. In contrast, cigarette smoking does not appear to be a risk factor for adenocarcinoma. (See",
"      <a class=\"local\" href=\"#H175461\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many women with cervical adenocarcinoma are asymptomatic. When symptoms occur, women are most likely to present with postcoital bleeding. (See",
"      <a class=\"local\" href=\"#H175741\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical adenocarcinoma is diagnosed with a cervical biopsy. Conization is required to define a microinvasive lesion and a negative margin is required to confirm the diagnosis. (See",
"      <a class=\"local\" href=\"#H175763\">",
"       'Diagnosis and staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The staging system used for cervical adenocarcinoma is the same as for SCC (",
"      <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"       table 2",
"      </a>",
"      ). We usually perform both a",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      and an MRI in with microscopically invasive and more advanced cervical adenocarcinoma to help guide treatment. (See",
"      <a class=\"local\" href=\"#H175763\">",
"       'Diagnosis and staging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291065774\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550396746\">",
"    <span class=\"h3\">",
"     Microinvasive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of microinvasive (stage IA1 to IA2) cervical adenocarcinoma depends upon patient age and desire to maintain fertility. The prognosis of microinvasive disease is excellent, and conservative, nonradical surgery is appropriate for some patients. (See",
"    <a class=\"local\" href=\"#H553368259\">",
"     'Microinvasive (IA1-IA2) disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most women with stage IA1 cervical adenocarcinoma, we suggest simple hysterectomy rather than radical hysterectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Pelvic lymphadenectomy is not necessary. Conization is a reasonable option in women who wish to preserve fertility and who do not have lymphovascular space invasion.",
"     </li>",
"     <li>",
"      For women with stage IA2 cervical adenocarcinoma, we suggest modified radical hysterectomy rather than simple hysterectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also perform pelvic lymphadenectomy in these women. Radical trachelectomy is a reasonable option in women who wish to preserve fertility and who do not have lymph node metastases",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      widespread evidence of lymphovascular space invasion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96574748\">",
"    <span class=\"h3\">",
"     Invasive disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most women with stage IB1 or IIA1 cervical adenocarcinoma who are appropriate surgical candidates, we suggest initial surgery (radical hysterectomy, bilateral salpingo-oophorectomy, plus pelvic lymph node dissection, as well as paraaortic lymph node dissection in patients with high risk tumors) rather than primary chemoradiotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H553367459\">",
"       'Invasive early stage (IB1-IIA) disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H381109989\">",
"       'Role and extent of lymphadenectomy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The presence of positive or close resection margins, positive lymph nodes, or microscopic parametrial involvement indicates a high risk for recurrence. As with SCC, we recommend postoperative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based concomitant chemoradiotherapy rather than adjuvant RT alone for these women (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Although the optimal regimen has not been established, we suggest weekly cisplatin (40",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      to a cumulative dose of at least 200",
"      <span class=\"nowrap\">",
"       mg/m2)",
"      </span>",
"      during RT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H453095097\">",
"       'Indications for adjuvant therapy after hysterectomy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H546744743#H546744743\">",
"       \"Management of early stage cervical cancer\", section on 'Primary therapy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      As with SCC, we recommend adjuvant RT after hysterectomy for women who are at intermediate-risk of recurrence (large tumor size, deep cervical stromal invasion to the middle or deep one-third, or lymphovascular space invasion) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest adding concomitant chemotherapy to adjuvant RT for women with intermediate-risk disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H453095097\">",
"       'Indications for adjuvant therapy after hysterectomy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H546744743#H546744743\">",
"       \"Management of early stage cervical cancer\", section on 'Primary therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women with locoregionally advanced stage IIB to IVA disease, those with earlier stage disease and bulky tumor (ie, stage IB2, IIA2, (",
"      <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"       table 2",
"      </a>",
"      )), or whose initial imaging studies suggest lymph node involvement, or if there are palpable lymph nodes, or pretreatment identification of other risk factors suggesting the need for adjuvant therapy after surgery (eg, tumor size &gt;4 cm), we suggest initial radiotherapy rather than surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      In all cases, we suggest the use of concomitant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy for women who undergo definitive RT for primary disease (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Although the optimal regimen has not been established, we suggest weekly cisplatin (40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      to a cumulative dose of at least 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      during RT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of locally advanced cervical cancer\", section on 'Primary chemoradiation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The role of preirradiation therapeutic lymphadenectomy in patients undergoing primary chemoradiotherapy is controversial. In general, we do not suggest its use, given the lack of definitive data that lymphadenectomy improves survival. However, this is a controversial area, and some clinicians would recommend removal of suspicious nodes in good surgical candidates using an extraperitoneal lymph node approach if feasible [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H453095633\">",
"       'Role of therapeutic lymphadenectomy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Although there are no data proving benefit for this approach, a simple extrafascial hysterectomy could be considered following chemoradiotherapy for those patients with early stage disease and no evidence of nodal involvement who have an initially large cervical lesion (&gt;7 cm), lower uterine segment involvement, or a high posttreatment residual tumor volume (See",
"      <a class=\"local\" href=\"#H553367459\">",
"       'Invasive early stage (IB1-IIA) disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with locoregionally advanced disease, we suggest not pursuing neoadjuvant chemotherapy followed by hysterectomy outside of the context of a clinical trial (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H453095363\">",
"       'Neoadjuvant chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2502369\">",
"    <span class=\"h4\">",
"     Prognosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, for patients with small tumors &lt;2 cm in size without LVSI, the survival difference between adenocarcinoma and SCC is negligible. Surgical management results in low recurrence rates and high overall survival rates with no differences in outcome related to histologic type. (See",
"      <a class=\"local\" href=\"#H1362292\">",
"       'Prognostic factors and differences in outcome compared to SCC'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As tumor stage advances, adenocarcinoma is associated with inferior survival, stage for stage. The incidence of lymph node metastases is higher for adenocarcinoma as compared to SCC, and survival rates are significantly worse for those with positive lymph nodes compared to similar patients with SCC.",
"     </li>",
"     <li>",
"      For patients with tumor size &gt;4 cm, and more locoregionally advanced (IIB to IVA) disease, distant failure rates are high, and distant failure is more common when chemotherapy is omitted [",
"      <a class=\"abstract\" href=\"UTD.htm?6/49/6938/abstract/4,61\">",
"       4,61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291065806\">",
"    <span class=\"h3\">",
"     Disseminated, recurrent, or persistent disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exenterative surgery is an option only for those few patients with centrally relapsed disease. (See",
"      <a class=\"local\" href=\"#H453095659\">",
"       'Surgery and/or RT for localized recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with a good performance status who wish to receive chemotherapy, and who are able to tolerate it, we suggest a platinum-based combination regimen plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      in the first line setting rather than chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients who are not candidates for bevacizumab should receive combination chemotherapy. (See",
"      <a class=\"local\" href=\"#H453095652\">",
"       'Chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link&amp;anchor=H2177909474#H2177909474\">",
"       \"Management of recurrent or metastatic cervical cancer\", section on 'First-line treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link&amp;anchor=H104509204#H104509204\">",
"       \"Management of recurrent or metastatic cervical cancer\", section on 'Metastatic disease'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The choice of the specific regimen should be based upon prior toxicity, preexisting morbidity, scheduling considerations, and patient preference. A standard regimen is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H453095652\">",
"       'Chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link&amp;anchor=H104509204#H104509204\">",
"       \"Management of recurrent or metastatic cervical cancer\", section on 'Metastatic disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical resection is an alternative to chemotherapy for highly selected patients with isolated, potentially resectable pulmonary metastases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link&amp;anchor=H8#H8\">",
"       \"Surgical resection of pulmonary metastases: Outcomes by histology\", section on 'Gynecologic cancers'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=see_link\">",
"       \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women with a poor performance status and those who progress following first-line therapy, acceptable options include single agent chemotherapy, best supportive care,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      palliative RT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link&amp;anchor=H85099849#H85099849\">",
"       \"Management of recurrent or metastatic cervical cancer\", section on 'Second-line therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link&amp;anchor=H16#H16\">",
"       \"Management of recurrent or metastatic cervical cancer\", section on 'Management of acutely symptomatic patients'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     SEER data for 2003-2007:  file://seer.cancer.gov/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/2\">",
"      Alfsen GC, Thoresen SO, Kristensen GB, et al. Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups: a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990. Cancer 2000; 89:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/3\">",
"      Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: a unique cervical cancer. Gynecol Oncol 2010; 116:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/4\">",
"      Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 1995; 59:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/5\">",
"      Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. Gynecol Oncol 2000; 78:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/6\">",
"      Plaxe SC, Saltzstein SL. Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol Oncol 1999; 75:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/7\">",
"      Castellsagu&eacute; X, D&iacute;az M, de Sanjos&eacute; S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/8\">",
"      Dahlstr&ouml;m LA, Ylitalo N, Sundstr&ouml;m K, et al. Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer 2010; 127:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/9\">",
"      Tornesello ML, Losito S, Benincasa G, et al. Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol Oncol 2011; 121:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/10\">",
"      Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer 2005; 103:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/11\">",
"      International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006; 118:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/12\">",
"      Quint KD, de Koning MN, van Doorn LJ, et al. HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix. Gynecol Oncol 2010; 117:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/13\">",
"      Madeleine MM, Daling JR, Schwartz SM, et al. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev 2001; 10:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/14\">",
"      Lacey JV Jr, Swanson CA, Brinton LA, et al. Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer 2003; 98:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/15\">",
"      Lacey JV Jr, Brinton LA, Barnes WA, et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol 2000; 77:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/16\">",
"      Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/17\">",
"      Young RH, Clement PB. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology 2002; 41:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/18\">",
"      Wang SS, Sherman ME, Silverberg SG, et al. Pathological characteristics of cervical adenocarcinoma in a multi-center US-based study. Gynecol Oncol 2006; 103:541.",
"     </a>",
"    </li>",
"    <li>",
"     Wright, TC, Ferenczy, A, Kurman, RJ. Carcinoma and other tumors of the cervix. In: Blaustein&rsquo;s Pathology of the Female Genital Tract., 4th edition, Robert J. Kurman (Ed), Springer-Verlag, New York 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/20\">",
"      Schorge JO, Lee KR, Flynn CE, et al. Stage IA1 cervical adenocarcinoma: definition and treatment. Obstet Gynecol 1999; 93:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/21\">",
"      Kilgore LC, Soong SJ, Gore H, et al. Analysis of prognostic features in adenocarcinoma of the cervix. Gynecol Oncol 1988; 31:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/22\">",
"      Eifel PJ, Morris M, Oswald MJ, et al. Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases. Cancer 1990; 65:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/23\">",
"      Eifel PJ, Burke TW, Delclos L, et al. Early stage I adenocarcinoma of the uterine cervix: treatment results in patients with tumors less than or equal to 4 cm in diameter. Gynecol Oncol 1991; 41:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/24\">",
"      Kastritis E, Bamias A, Efstathiou E, et al. The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. Gynecol Oncol 2005; 99:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/25\">",
"      Lee KB, Lee JM, Park CY, et al. What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case-control study. Int J Gynecol Cancer 2006; 16:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/26\">",
"      Katanyoo K, Sanguanrungsirikul S, Manusirivithaya S. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. Gynecol Oncol 2012; 125:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/27\">",
"      Macdonald OK, Chen J, Dodson M, et al. Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix. Am J Clin Oncol 2009; 32:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/28\">",
"      Davy ML, Dodd TJ, Luke CG, Roder DM. Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival. Obstet Gynecol 2003; 101:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/29\">",
"      Nakanishi T, Ishikawa H, Suzuki Y, et al. A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2000; 79:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/30\">",
"      Lee YY, Choi CH, Kim TJ, et al. A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA. Gynecol Oncol 2011; 120:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/31\">",
"      Galic V, Herzog TJ, Lewin SN, et al. Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol 2012; 125:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/32\">",
"      Berek JS, Castaldo TW, Hacker NF, et al. Adenocarcinoma of the uterine cervix. Cancer 1981; 48:2734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/33\">",
"      Kleine W, Rau K, Schwoeorer D, Pfleiderer A. Prognosis of the adenocarcinoma of the cervix uteri: a comparative study. Gynecol Oncol 1989; 35:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/34\">",
"      Burger RA, Monk BJ, Kurosaki T, et al. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 1996; 88:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/35\">",
"      Im SS, Wilczynski SP, Burger RA, Monk BJ. Early stage cervical cancers containing human papillomavirus type 18 DNA have more nodal metastasis and deeper stromal invasion. Clin Cancer Res 2003; 9:4145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/36\">",
"      Irie T, Kigawa J, Minagawa Y, et al. Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. Eur J Surg Oncol 2000; 26:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/37\">",
"      Shingleton HM, Bell MC, Fremgen A, et al. Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? Cancer 1995; 76:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/38\">",
"      Shimada M, Kigawa J, Nishimura R, et al. Ovarian metastasis in carcinoma of the uterine cervix. Gynecol Oncol 2006; 101:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/39\">",
"      Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006; 65:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/40\">",
"      Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/41\">",
"      Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/42\">",
"      Reynolds EA, Tierney K, Keeney GL, et al. Analysis of outcomes of microinvasive adenocarcinoma of the uterine cervix by treatment type. Obstet Gynecol 2010; 116:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/43\">",
"      Hou J, Goldberg GL, Qualls CR, et al. Risk factors for poor prognosis in microinvasive adenocarcinoma of the uterine cervix (IA1 and IA2): a pooled analysis. Gynecol Oncol 2011; 121:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/44\">",
"      Smith HO, Qualls CR, Romero AA, et al. Is there a difference in survival for IA1 and IA2 adenocarcinoma of the uterine cervix? Gynecol Oncol 2002; 85:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/45\">",
"      Schorge JO, Lee KR, Lee SJ, et al. Early cervical adenocarcinoma: selection criteria for radical surgery. Obstet Gynecol 1999; 94:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/46\">",
"      Sutton GP, Bundy BN, Delgado G, et al. Ovarian metastases in stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1992; 166:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/47\">",
"      Baalbergen A, Veenstra Y, Stalpers LL, Ansink AC. Primary surgery versus primary radiation therapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. Cochrane Database Syst Rev 2010; :CD006248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/48\">",
"      Baalbergen A, Veenstra Y, Stalpers L. Primary surgery versus primary radiotherapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. Cochrane Database Syst Rev 2013; CD006248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/49\">",
"      Keys HM, Bundy BN, Stehman FB, et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol 2003; 89:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/50\">",
"      Huang YT, Wang CC, Tsai CS, et al. Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 2011; 80:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/51\">",
"      Lea JS, Sheets EE, Duska LR, et al. Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection. Gynecol Oncol 2002; 84:285.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/53\">",
"      Lea JS, Sheets EE, Wenham RM, et al. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol 2002; 84:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/54\">",
"      Lissoni A, Gabriele A, Gorga G, et al. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol 1997; 8:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/55\">",
"      Iwasaka T, Fukuda K, Hara K, et al. Neoadjuvant chemotherapy with mitomycin C, etoposide, and cisplatin for adenocarcinoma of the cervix. Gynecol Oncol 1998; 70:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/56\">",
"      Zanetta G, Lissoni A, Gabriele A, et al. Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma. Gynecol Oncol 1997; 64:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/57\">",
"      Benedetti-Panici P, Greggi S, Scambia G, et al. Locally advanced cervical adenocarcinoma: is there a place for chemo-surgical treatment? Gynecol Oncol 1996; 61:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/58\">",
"      Umesaki N, Izumi R, Fushiki H, et al. Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease. Gynecol Oncol 1999; 75:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/59\">",
"      Nagao S, Fujiwara K, Oda T, et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol 2005; 96:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/60\">",
"      Rein DT, Kurbacher CM, Breidenbach M, et al. Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study. Gynecol Oncol 2002; 87:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/49/6938/abstract/61\">",
"      Monk BJ, Wang J, Im S, et al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol 2005; 96:721.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13929 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_49_6938=[""].join("\n");
var outline_f6_49_6938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H176666\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H553367437\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175461\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H553367444\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175741\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175763\">",
"      DIAGNOSIS AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453094955\">",
"      Staging system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453094962\">",
"      Staging workup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1362292\">",
"      PROGNOSTIC FACTORS AND DIFFERENCES IN OUTCOME COMPARED TO SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H96574101\">",
"      Differences in patterns of dissemination and recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H96574449\">",
"      Differences in treatment response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H553367451\">",
"      SPECIFIC MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H553368259\">",
"      Microinvasive (IA1-IA2) disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H553367459\">",
"      Invasive early stage (IB1-IIA) disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10754335\">",
"      - Posttreatment extrafascial hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H381109989\">",
"      - Role and extent of lymphadenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H453095097\">",
"      - Indications for adjuvant therapy after hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H553367466\">",
"      Locoregionally advanced (IIB-IVA) disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H453095633\">",
"      - Role of therapeutic lymphadenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H453095363\">",
"      - Neoadjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H553367473\">",
"      Stage IVB, persistent and recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H453095659\">",
"      - Surgery and/or RT for localized recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H453095652\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H550393653\">",
"      - Surgery for metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H553367480\">",
"      Fertility preservation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H553367487\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H176666\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H291065774\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H550396746\">",
"      - Microinvasive disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H96574748\">",
"      - Invasive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2502369\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H291065806\">",
"      - Disseminated, recurrent, or persistent disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/13929\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/13929|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/38/2668\" title=\"table 1\">",
"      Histopathology cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/6/33902\" title=\"table 2\">",
"      Staging cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/53/27485\" title=\"table 3\">",
"      Survival cervical adenocarcinoma versus SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/16/16651\" title=\"table 4\">",
"      Differences in cervical CA relapse by histology and stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/29/13788\" title=\"table 5\">",
"      Types of hysterectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37736?source=related_link\">",
"      Cervical adenocarcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9898?source=related_link\">",
"      Fertility sparing surgery for invasive cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/42/17064?source=related_link\">",
"      Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=related_link\">",
"      Invasive cervical cancer: Staging and evaluation of lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=related_link\">",
"      Management of early stage cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=related_link\">",
"      Management of locally advanced cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=related_link\">",
"      Management of recurrent or metastatic cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28163?source=related_link\">",
"      Patient information: Cervical cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=related_link\">",
"      Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5498?source=related_link\">",
"      Small cell neuroendocrine carcinoma of the cervix",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=related_link\">",
"      Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=related_link\">",
"      Surgical resection of pulmonary metastases: Outcomes by histology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_49_6939="Treatment guidelines osteoporosis";
var content_f6_49_6939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for pharmacologic intervention in postmenopausal women and men &ge;50 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        History of hip or vertebral fracture.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T-score &le;-2.5 (DXA) at the femoral neck or spine, after appropriate evaluation to exclude secondary causes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T-score between -1 and -2.5 at the femoral neck or spine, and a 10-year probability of hip fracture &ge;3 percent or a 10-year probability of any major osteoporosis-related fracture &ge;20 percent based upon the US-adapted WHO algorithm.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        NOF's Clinician's Guide to Prevention and Treatment of Osteoporosis.",
"        <a href=\"file://nof.org/files/nof/public/content/file/344/upload/159.pdf\">",
"         file://nof.org/files/nof/public/content/file/344/upload/159.pdf",
"        </a>",
"        , accessed November 28, 2012.",
"       </li>",
"       <li>",
"        Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:1802.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_49_6939=[""].join("\n");
var outline_f6_49_6939=null;
var title_f6_49_6940="Causes elevated D-dimer";
var content_f6_49_6940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F60881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F60881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders associated with increased plasma levels of fibrin D-dimer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Arterial thromboembolic disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Myocardial infarction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Stroke",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Acute limb ischemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Atrial fibrillation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Intracardiac thrombus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Venous thromboembolic disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Deep vein thrombosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Pulmonary embolism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disseminated intravascular coagulation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Preeclampsia and eclampsia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abnormal fibrinolysis; use of thrombolytic agents",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cardiovascular disease, congestive failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe infection/sepsis/inflammation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Surgery/trauma (eg, tissue ischemia, necrosis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Systemic inflammatory response syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vasoocclusive episode of sickle cell disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe liver disease (decreased clearance)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Malignancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Renal disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Nephrotic syndrome (eg, renal vein thrombosis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Acute renal failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Chronic renal failure and underlying cardiovascular disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Normal pregnancy",
"       </p>",
"       <p>",
"        Venous malformations",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_49_6940=[""].join("\n");
var outline_f6_49_6940=null;
var title_f6_49_6941="Infection risk by type of neutropenia";
var content_f6_49_6941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infection risk by type of neutropenia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Marrow reserve",
"       </td>",
"       <td class=\"subtitle1\">",
"        T/B immunity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relation to ANC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Low to no risk",
"       </td>",
"       <td>",
"        Chronic benign",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethnic",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post infectious",
"       </td>",
"       <td>",
"        Normal/mild decrease",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Yes/no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersplenism",
"       </td>",
"       <td>",
"        Normal/increased",
"       </td>",
"       <td>",
"        Depends on cause of hypersplenism",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Moderate risk",
"       </td>",
"       <td>",
"        Post infectious",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Yes/no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug induced",
"       </td>",
"       <td>",
"        Decreased/normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclic",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nutritional",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Normal/variable",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immune (antibody mediated)",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Abnormal",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immune (SLE, CVID)",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Abnormal T/B",
"       </td>",
"       <td>",
"        No/yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"7\">",
"        High risk",
"       </td>",
"       <td>",
"        LDLGL, PWCA",
"       </td>",
"       <td>",
"        Very decreased to absent",
"       </td>",
"       <td>",
"        Abnormal T cells",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shwachman",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Normal/?",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kostmann",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Normal/?",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug induced",
"       </td>",
"       <td>",
"        Very decreased to absent",
"       </td>",
"       <td>",
"        Abnormal",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antineoplastic chemotherapy",
"       </td>",
"       <td>",
"        Very decreased to absent",
"       </td>",
"       <td>",
"        Abnormal T/B",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aplastic anemia",
"       </td>",
"       <td>",
"        Decreased/absent",
"       </td>",
"       <td>",
"        Probably abnormal T cells",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marrow infiltration/MDS/leukemia",
"       </td>",
"       <td>",
"        Decreased/absent",
"       </td>",
"       <td>",
"        Probably abnormal",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ANC: absolute neutrophil count; SLE: systemic lupus; CVID: common variable immunodeficiency; LDLGL: lymphoproliferative disorders of large granular lymphocytes; PWCA: pure white cell aplasia; MDS: myelodysplastic syndrome.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_49_6941=[""].join("\n");
var outline_f6_49_6941=null;
var title_f6_49_6942="Contents: Peds psychosocial emergencies";
var content_f6_49_6942=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?10/42/10926\">",
"       Adult and Pediatric Emergency Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Peds psychosocial emergencies",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Peds psychosocial emergencies",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/34/7718\">",
"           Child abuse: Anatomy and pathogenesis of retinal hemorrhages after abusive head trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/13/32985\">",
"           Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/19/40249\">",
"           Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/7/20602\">",
"           Child abuse: Eye findings in children with abusive head trauma (AHT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/2/19497\">",
"           Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/5/35927\">",
"           Child abuse: Social and medicolegal issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/62/18408\">",
"           Child neglect and emotional abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/27/23990\">",
"           Differential diagnosis of suspected child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/23/11641\">",
"           Differential diagnosis of the orthopedic manifestations of child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/11/38071\">",
"           Evaluation and management of suicidal behavior in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35258\">",
"           Evaluation of sexual abuse in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/15/11510\">",
"           Management and sequelae of sexual abuse in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/16/36104\">",
"           Munchausen syndrome by proxy (medical child abuse)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/30/13802\">",
"           Orthopedic aspects of child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/42/40617\">",
"           Peer violence and violence prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/19/24890\">",
"           Physical abuse in children: Diagnostic evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/54/26473\">",
"           Physical abuse in children: Epidemiology and clinical manifestations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/17/23834\">",
"           Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-990C108AD3-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f6_49_6942=[""].join("\n");
var outline_f6_49_6942=null;
var title_f6_49_6943="Testing and treatment for HH";
var content_f6_49_6943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Algorithm for the testing and treatment for hereditary hemochromatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 470px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An algorithm can provide some further direction regarding testing and treatment for HH. The algorithm is modified from the version used in the previous AASLD guidelines. For screening purposes, the serum ferritin is considered elevated if it is &gt;200 ng/mL in men or &gt;150 ng/mL in women.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:328. Copyright &copy; 2011 American Association for the Study of Liver Diseases. Reproduced with permission of John Wiley &amp; Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_49_6943=[""].join("\n");
var outline_f6_49_6943=null;
